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Title: Peri-implantitis Prognosis Using Metabolomic Biomarkers in Peri-
Implant Crevicular Fluid: A Longitudinal Study.  
Background: Peri-implant diseases, peri-implantitis (PI) and peri-implant 
mucositis (PIM), are highly prevalent in subjects with dental implants. 
Despite this prevalence, diagnosing peri-implant disease (PID) remains 
challenging because of lack of accuracy and precision of periodontal probing 
and dental radiographs. Furthermore, these diagnostic tools document 
history of disease rather than current disease activity. There is no current 
model to predict the progression of PID. Biomarkers are commonly used in 
medicine to objectively determine disease state, or responses to a 
therapeutic intervention. Biomarkers in peri-implant crevicular fluid (PICF) 
show promise in their diagnostic and prognostic value. Metabolomic analysis 
of PICF quantifies molecules associated with host and bacterial metabolism 
may reflect on pathophysiology of peri-implantitis. Un-targeted metabolomics 
allows the discovery of unknown biomarkers without bias to correlate them 
with peri-implantitis and its progression.  
Aim: We hypothesize that the simple metabolites in PICF are predictors of 
future peri-implantitis progression. We aim to define the unique set of 
metabolites in the PICF that establish a reliable method for early prediction of 
bone-loss progression in peri-implantitis.  
Methods: Clinical and radiographic examinations and PICF samples were 
collected from 130 implants in 71 subjects at baseline, 6, 12, 18 and 24 
months. At baseline, 59 implants were healthy (bone loss < 2mm; PD £ 
4mm), 33 implants had PI (bone loss ≥ 3mm; PD ≥ 6mm) and 38 other 
implants had bone loss ≥ 2mm and <3mm and PD 5mm. Radiographic bone 
level changes of 112 implants and relative metabolites in PICF samples were 
measured at each 6 months interval using proton nuclear magnetic 
resonance (H-NMR) spectroscopy. MetaboAnalyst 5.0 software correlated 
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metabolite levels with radiographic bone changes of ≥ 1mm within a 6-month 
interval. 
Results: In the cross-sectional component at baseline, univariate ROC curve 
analysis demonstrated that the Cadaverine/Lysine signature was significantly 
correlated with peri-implantitis (AUC= 0.76; 95% CI 0.658-0.855, p< 0.000) 
versus healthy implants. While alpha ketoglutarate was significantly 
correlated with healthy implants (AUC= 0.706; 95% CI 0.593-0.819; p= 
0.002). In the longitudinal component, the metabolite levels in PICF of 
untreated diseased implants that demonstrated progressive radiographic 
bone loss of ≥ 1mm within a 6-month interval (group A, n=6) were compared 
to the metabolites of healthy-non-progressing implants (group B, n=26) and 
to diseased-non-progressing implants (group C, n=8).  Proline and 1-3-
diaminopropane levels could predict future bone loss of ≥ 1mm (AUC= 0.917 
and 0.854 respectively) whereas glucose and arginine levels could predict 
the absence of bone loss in group C and group B respectively (AUC= 0.896 
and 0.801) although statistical significance was not reached for all 4 
metabolites. Biotin and propionate levels were higher in group C compared 
group A and group B (ANOVA p< 0.001; AUC biotin= 0.889; AUC propionate= 
0.87). Valine levels were higher in both group A and group C compared to 
group B (p= 0.002; AUC= 0.841). 
Conclusions: PICF metabolites identified using H-NMR spectroscopy 
mapped a specific metabolomic profile able to identify implants with peri-
implantitis versus healthy implants with moderate accuracy. Furthermore, 
specific metabolites discriminated between progressive disease versus non-
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Teeth may be lost due to trauma or infectious diseases. Dental implants 
are one of the options to replace missing teeth (Renvert, Persson et al. 2018). 
There has been a significant increase in the incidence of dental implant 
insertions among adults in the United States by 14% per year from 1999 to 
2016. Six percent of adults in the U.S. had benefited from dental implants by 
2016. The dental implant prevalence among U.S. adults could reach 17% by 
2026 if the trend continues at the current pace (Elani, Starr et al. 2018).   
As implants are becoming more common, associated disease prevalence 
shows a positive correlation. Peri-implant mucositis (PIM) is defined as an 
inflammatory lesion of the soft tissues surrounding an endosseous implant 
without loss of supporting bone or continuing marginal bone loss (Heitz-
Mayfield and Salvi 2018). On the other hand, peri-implantitis (PI) is a 
pathological condition occurring in tissues around dental implants, 
characterized by inflammation in the peri-implant connective tissue and 
progressive loss of supporting bone (Schwarz, Derks et al. 2018). According 
to a meta-analysis and systematic review, the estimated prevalence of peri-
implantitis is 22% and peri-implant mucositis is 43% (Derks and Tomasi 
2015). The absence of signs of clinical inflammation is considered peri-
implant health (Araujo and Lindhe 2018).  
There was a wide heterogeneity in defining peri-implantitis. Clinicians 
attempted to differentiate how much radiographic bone loss would be 
indicative of disease, as opposed to the expected post-placement bone 
remodeling. The current radiographic criteria for peri-implantitis is defined as 
bone loss of ≥ 2 mm according to the 2017 World Workshop on the 
Classification of Periodontal and Peri-implant Diseases and Conditions 
(Berglundh, Armitage et al. 2018). In the absence of initial radiographs and 
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probing depths, radiographic evidence of bone loss of ≥ 3 mm and/or probing 
depths ≥6 mm in conjunction with profuse bleeding fits the definition for PI.  
The progression of PI was found to have an annual rate of bone loss of 
about 0.4 mm but in a non-linear and accelerating pattern (Derks, Schaller et 
al. 2016). Peri-implantitis often appears within the first few years after the 
implant is in function (Renvert, Persson et al. 2018). Plaque/biofilm is a 
principal etiological factor; except for some unusual factors such as implant 
fractures and iatrogenic errors. It has been shown that there is an increased 
risk of developing PI in patients who have a history of severe periodontitis, 
poor plaque control, and no regular maintenance care after implant therapy 
(Berglundh, Armitage et al. 2018).  
Destructive periodontal diseases are the result of environmental, host, 
and bacterial factors (Wolff, Dahlen et al. 1994). Similarly, PI exhibits a 
chronic inflammatory response to the bacterial biofilm on the tooth/implant 
surface (Heitz-Mayfield and Lang 2010). PIM precedes PI and the progression 
of PI appears to be faster than periodontitis around natural teeth (Schwarz, 
Derks et al. 2018). PIM is primarily caused by a disruption of the host–
microbe homeostasis at the implant–mucosa interface and is a reversible 
condition (Heitz-Mayfield and Salvi 2018). There is no consensus on which 
surgical intervention is most reliable in controlling peri-implantitis (Englezos, 
Cosyn et al. 2018).  
No one specific or unique bacteria has been identified in patients with 
peri-implant disease (PID). When compared with healthy implant sites, PI was 
associated with higher counts of 19 bacterial species, including 
Porphyromonas gingivalis and Tannerella forsythia (Schwarz, Derks et al. 
2018). When compared to periodontitis in natural teeth; PI was more 
frequently linked with opportunistic pathogens of bacterial, fungal and viral 
origins which points to a heterogenous infection (Schwarz, Derks et al. 2018). 
Some individuals are believed to be more susceptible to peri-implantitis. 
Current evidence indicates a potential influence of various gene 
polymorphisms in the pathogenesis of peri-implantitis; however, prospective 
clinical studies having sufficient sample size are currently lacking (Schwarz, 
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Derks et al. 2018). Gram-negative bacteria are the most important bacteria 
frequently isolated from the periodontal pockets of natural teeth, such as: 
Aggregatibacter actinomycetemcomitans, Eikenella corrodens, Fusobacterium 
nucleatum, Prevotella intermedia, Porphyromonas gingivalis and Tannerella 
forsythia (Patini, Staderini et al. 2018). However, a recent systematic review 
pointed out the importance of new pathogens such as: Desulfobulbus spp., 
Filifactor alocis and TM7 spp. in periodontal disease (Patini, Staderini et al. 
2018). Notably, periodontal disease around natural teeth is not caused by the 
presence of specific bacteria, but by changes in the levels of different species 
within the oral microbiome.  
The traditional clinical method to assess implant health includes a 
periodontal probe to measure the pocket depths and to observe bleeding 
upon probing. Unfortunately, this simple tool has limitations. The absence of a 
periodontal ligament around implants and the prosthetic design may make 
assessment of pocket probing depth measurements difficult to perform and 
interpret. Additionally, the implant mucosal seal may have less resistance to 
probing compared to natural teeth. This may lead to mechanically induced 
bleeding when probing around healthy implants. However, the healing of the 
epithelial attachment seems to be complete five days after clinical probing, 
hence, does not seem to jeopardize the longevity of implants according to an 
animal study (Etter, Hakanson et al. 2002). Radiographs should be 
standardized and compared to reference radiographs taken at the time the 
implant was placed in function. Furthermore, there is no practical model to 
predict the progression of PI (Renvert, Persson et al. 2018). Predicting 
disease progression is an essential component to formulate a prognosis. 
Treatment protocols cannot be easily compared without a valid prognosis. 
Non-surgical therapy of PI is often ineffective, and the treatment of choice is a 
surgical approach (Englezos, Cosyn et al. 2018). Surgical techniques may 
include open flap debridement with removal of the inflammatory tissue and 
mechanical and chemical decontamination of the exposed implant surface. 
Recontouring the bony architecture and smoothing of the implant surface may 
improve infection control. Regenerative procedures using a membrane and 
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bone graft substitutes attempting to partially fill the bony defects caused by 
peri-implantitis can be successful (Roccuzzo, Layton et al. 2018). Therapy of 
peri-implantitis followed by regular supportive care resulted in favorable 
clinical improvements and stable peri-implant bone levels in the majority of 
patients according to a systematic review (Sahrmann, Attin et al. 2011). 
The early diagnosis of PID and its rate of progression are a great 
challenge. Assessment of biomarkers may aid in the early detection of PI. 
Biomarkers may assist both in staging and grading of periodontitis in the case 
definition system of periodontitis (Tonetti, Greenwell et al. 2018). Peri-implant 
crevicular fluid (PICF), also described as peri-implant sulcular fluid (PISF), 
may contain biomarkers to diagnose and predict future disease which aids in 
choosing a specific treatment protocol. A biomarker is a parameter that is 
objectively measured and evaluated as an indicator of normal biological, 
pathogenic processes, or responses to a therapeutic intervention (Strimbu 
and Tavel 2010). Molecules in the gingival crevicular fluid (GCF) collected 
from natural teeth have been extensively studied. Substances such as lactate 
dehydrogenase and myeloperoxidase have been investigated to determine if 
they could be used as markers for periodontal pathology and in the success of 
treatment modalities (Wolff, Smith et al. 1988). Another approach was 
described in a recent report which found that measuring glycosylated 
hemoglobin in gingival crevicular blood was successfully used to screen for 
diabetes control in a dental office setting (Kim, Wolff et al. 2015). Most of the 
PI biomarker studies focused on pro-inflammatory cytokines, enzymes and 
bone metabolism proteins (Ma, Kitti et al. 2000, Ma, Kitti et al. 2003, Arikan, 
Buduneli et al. 2008, Schierano, Pejrone et al. 2008, Arikan, Buduneli et al. 
2011, Zani, Moss et al. 2016).  Table 1 lists keywords and abbreviations in 




Table 1. Keywords and abbreviations 
PI Peri-Implantitis 
PIM peri-implant mucositis 
PID peri-implant disease 
GCF Gingival crevicular fluid 
PICF peri-implant crevicular fluid 
MMP matrix metalloproteinase 
IL-1β Interleukin 1 beta 
IL-6 Interleukin-6 
IL-1ra interleukin-1 receptor antagonist 
TNFα tumor necrosis factor alpha 
GM-CSF granulocyte-macrophage colony-stimulating factor 
MIP-1α macrophage inflammatory protein-1α 
RANK receptor activator of nuclear factor kappa-Β 
RANKL receptor activator of nuclear factor kappa-Β ligand 
sRANKL soluble Receptor activator of nuclear factor kappa-Β ligand 
OPG osteoprotegerin 
TIMP tissue inhibitor of metalloproteinases 
MPO myeloperoxidase 
tPA tissue plasminogen activator 
TRAP tartrate-resistant acid phosphatase 
CatK cathepsin K 
PAI plasminogen activator inhibitor 
VEGF vascular endothelial growth factor 
ICTP C-telopeptide pyridinoline cross linkage of type I collagen 
α-KG Alpha ketoglutarate 
ELISA enzyme-linked immunosorbent assay 






2. LITERATURE REVIEW 
2.1. Gingival crevicular fluid & peri-implant crevicular fluid in health and 
disease  
GCF is a physiological fluid and an inflammatory exudate originating from 
the gingival plexus of blood vessels in the gingival corium, subjacent to the 
epithelium lining of the dentogingival space. GCF flows through the external 
basement membrane and the junctional epithelium to reach the gingival 
crevice. The composition of GCF can potentially be used to detect subclinical 
alterations in tissue metabolism, inflammatory-cell recruitment and connective 
tissue remodeling (Barros, Williams et al. 2016). Cytokines and enzymes 
located in the gingival tissues may lead to the degradation of connective 
tissue collagen and alveolar bone. These are host response factors from local 
host tissue reacting to the plaque biofilm. In the presence of disease, the 
volumes of GCF and PICF were similarly higher than in healthy sites, and 
GCF flow increases with an increase in the severity of gingival inflammation 
(Bevilacqua, Biasi et al. 2016). Significant positive correlations were noted 
between the concentrations of cytokines in PICF versus their levels in GCF 
around natural teeth (Recker, Avila-Ortiz et al. 2015). Another study 
compared the cytokine and bacterial levels from around implants versus teeth 
within the same individual (Gurlek, Gumus et al. 2017). There were many 
similarities but, also some differences in levels of IL-1β and soluble receptor 
activator nuclear factor kappa-B ligand (sRANKL) and bacterial species 
between peri-implant and periodontal sites in the same individuals, suggesting 
similar pathogenic mechanisms. Investigators compared crevicular fluid from 
diseased teeth and implants, and tested collagenase activity and 
collagenolytic matrix metalloproteinase (MMP) levels. Results indicated that 
peri-implantitis PICF contained higher active MMP-8 levels than GCF from 
similarly deep chronic periodontitis sites of natural teeth (Xu, Yu et al. 2008). 
A 10-year retrospective investigation comparing crevicular fluid biomarkers 
from implants and teeth concluded that increased levels of MMP-8 and IL-1β 
in PICF or GCF may be associated with inflammation around implants and 
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teeth while lower levels of MMP-1/TIMP-1 may be an indicator of disease 
progression around implants (Ramseier, Eick et al. 2016).  
 
2.2. PICF disease mediators (Cytokines) 
The gingival sulcus forms a unique ecological niche for microbial 
colonization. As the salivary film transitions at the crown to the gingival sulcus, 
its composition changes and the proportion of serum proteins increases due 
to the proximity with the crevicular fluid. The microbiota of the dental plaque 
biofilm drives the inflammatory process. The microbial biofilm in the gingival 
sulcus elicits inflammation in the surrounding connective tissue (Costalonga 
and Herzberg 2014). The imbalance between the bacterial challenge and host 
response at the soft tissue–implant interface triggers an inflammatory process 
(Wang, Garaicoa-Pazmino et al. 2016). Cytokines, such as Tumor necrosis 
factor alpha (TNFα), Interleukin-1-beta (IL-1β) and Interleukin-6 (IL-6) are 
released from cells of the gingival epithelium, dendritic cells, connective tissue 
fibroblasts, macrophages and neutrophils. In addition, a number of enzymes, 
such as matrix metalloproteinases, are produced by neutrophils, fibroblasts 
and osteoclasts, leading to the degradation of connective tissue collagen and 
alveolar bone (Barros, Williams et al. 2016). More than 90 different molecular 
components in GCF have been evaluated for potential periodontal disease 
diagnosis associated with the natural dentition (Loos and Tjoa 2005). To date, 
significantly fewer PICF components have been analyzed around implants.  
PI and periodontitis lesions exhibit critical histopathologic differences, 
which contribute to the understanding of dissimilarities in onset and 
progression between the two diseases (Carcuac and Berglundh 2014). 
Histologically, PI lesions extend apical to the junctional epithelium and contain 
large numbers and densities of plasma cells, macrophages and neutrophils. 
PI lesions are larger than those found at PIM sites (Berglundh, Armitage et al. 
2018). In contrast to periodontitis, PI lesions are more than twice the size and 
contain a significantly larger area, numbers, and densities of Syndecan-1 
(CD138)+, scavenger receptor class D – member 1 (CD68)+, and 
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mieloperoxidase (MPO)+ cells. Furthermore, larger densities of vascular 
structures are seen in the connective tissue area lateral to the infiltrated 
connective tissue than within the infiltrate in PI lesions (Carcuac and 
Berglundh 2014).  
 
2.3. PICF research in peri-implantitis: Methods of sampling and analysis 
A variety of methods have been used to sample and analyze components 
of PICF to diagnose PI. The most common method used to collect PICF has 
been paper strips inserted into the crevice for typically 30 seconds. PICF is 
then absorbed onto the strips. After elution from the strips into a buffer or 
diluent, the fluid is evaluated utilizing biomarker-specific assays. Studies have 
also used paper cones, membranes and microcapillary pipettes to collect 
PICF.  
The PICF volume is dependent upon the level of inflammation and pocket 
depth. The quantity of components collected in a deep and inflamed pocket 
would in all likelihood be higher than in healthy sulci. The concentration 
versus the quantity of the collected PICF components may offer more value in 
the search of valid biomarkers; however, this may be controversial 
(Chatzopoulos, Mansky et al. 2019). Enzyme-linked immunosorbent assay 
(ELISA), flow cytometry, Luminex and Spectrophotometry were the most 
utilized assays in PICF research. Typically, studies used ELISA to analyze 
PICF and evaluated one to two cytokines (Duarte, Serrao et al. 2016).  
 
2.4. Analysis of the current literature on PICF biomarkers 
2.4.1. PICF molecules investigated 
Most PI biomarker studies analyzed the correlation of enzymes and 
cytokines between healthy and diseased implants. Such components include 
proinflammatory cytokines such as TNFα, IL-1β, IL-6, IL-17 and anti-
inflammatory cytokines such as IL-10 (Schierano, Pejrone et al. 2008, Duarte, 
de Mendonca et al. 2009, Casado, Canullo et al. 2013, Wohlfahrt, Aass et al. 
2014, Faot, Nascimento et al. 2015, Zani, Moss et al. 2016, Gurlek, Gumus et 
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al. 2017). Other cytokines analyzed were interleukin-1 receptor antagonist (IL-
1ra) and Granulocyte-macrophage colony-stimulating factor (GM-CSF) (Zani, 
Moss et al. 2016). Some studies investigated chemokines such as IL-8 and 
macrophage inflammatory protein-1α (MIP-1α) (Hall, Pehrson et al. 2015, 
Bhavsar, Miller et al. 2019). Other reported investigations analyzed bone 
metabolism markers such as Receptor activator nuclear factor kappa-B ligand 
(RANKL), Receptor activator nuclear factor κ B (RANK), Osteoprotegerin 
(OPG) and Osteocalcin (Monov, Strbac et al. 2006, Arikan, Buduneli et al. 
2008, Arikan, Buduneli et al. 2011, Rakic, Lekovic et al. 2013, Dursun and 
Tozum 2016, Cakal, Efeoglu et al. 2018). Other trials investigated enzymes 
such as matrix metalloproteinases (MMP1, MMP8, MMP9, MMP13), tissue 
inhibitor of metalloproteinases 1&2 (TIMP) (Ma, Kitti et al. 2000, Ma, Kitti et al. 
2003, Sorsa, Tervahartiala et al. 2011, Arakawa, Uehara et al. 2012, 
Basegmez, Yalcin et al. 2012, Wohlfahrt, Aass et al. 2014, Ramseier, Eick et 
al. 2016, Ghassib, Chen et al. 2019), Elastase, Myeloperoxidase (MPO) 
(Dursun and Tozum 2016),  tissue plasminogen activator (tPA), tartrate-
resistant acid phosphatase (TRAP), cathepsin K (CatK) (Strbac, Monov et al. 
2006, Yamalik, Gunday et al. 2012, Hall, Pehrson et al. 2015, Dursun and 
Tozum 2016). Some authors reported on other PICF components such as 
plasminogen activator inhibitor 2 (PAI-2), vascular endothelial growth factor 
(VEGF), prostaglandin E2, KLIKK-protease genes and miropin (Hall, Pehrson 
et al. 2015, Dursun and Tozum 2016, Zani, Moss et al. 2016, Eckert, 
Mizgalska et al. 2018). A summary of commonly investigated PICF 




Table 2. Summary of commonly investigated peri-implant crevicular 
fluid (PICF) biomarkers in peri-implantitis. 
Biomarker Summary References 
   
Cytokines:   
TNFα 
higher levels in 
diseased vs 
healthy implants 
(Duarte, de Mendonca et al. 2009, 
Faot, Nascimento et al. 2015, Zani, 
Moss et al. 2016, Ghassib, Chen et 
al. 2019)  
IL-1β 
higher levels in 
diseased vs 
healthy implants 
(Panagakos, Aboyoussef et al. 
1996, Murata, Tatsumi et al. 2002, 
Schierano, Pejrone et al. 2008, 
Casado, Canullo et al. 2013, Hall, 
Pehrson et al. 2015, Ramseier, Eick 
et al. 2016, Wang, Garaicoa-
Pazmino et al. 2016, Gurlek, Gumus 
et al. 2017, Ghassib, Chen et al. 





(Casado, Canullo et al. 2013, Zani, 
Moss et al. 2016) 
   
Bone markers:   
sRANKL, RANK, 
OPG 





(Monov, Strbac et al. 2006, Arikan, 
Buduneli et al. 2008, Arikan, 
Buduneli et al. 2011, Rakic, Lekovic 
et al. 2013)    
Osteocalcin 





(Dursun and Tozum 2016, Cakal, 
Efeoglu et al. 2018)  
   
Enzymes:   
MMP-1 
higher levels in 
diseased vs 
healthy implants 
(Nomura, Ishii et al. 2000)  
MMP-8 
higher levels in 
diseased vs 
healthy implants 
(Ma, Kitti et al. 2000, Nomura, Ishii 
et al. 2000, Sorsa, Tervahartiala et 
al. 2011, Arakawa, Uehara et al. 
2012, Basegmez, Yalcin et al. 2012, 
Wohlfahrt, Aass et al. 2014, 
Ramseier, Eick et al. 2016, Ghassib, 




higher levels in 
diseased vs 
healthy implants 
(Ma, Kitti et al. 2003)  
MMP-13 
higher levels in 
diseased vs 
healthy implants 
(Ma, Kitti et al. 2000)     
Myeloperoxidase 
higher levels in 
diseased vs 
healthy implants 
(Dursun and Tozum 2016) 
Elastase 
higher levels in 
diseased vs 
healthy implants 
(Dursun and Tozum 2016) 
Cathepsin K 
(CatK) 
higher levels in 
diseased vs 
healthy implants 
(Strbac, Monov et al. 2006, Yamalik, 
Gunday et al. 2012, Hall, Pehrson et 




2.4.2. Proinflammatory cytokines 
Most investigations including systematic reviews and meta-analyses 
focused on the assessment of proinflammatory cytokines IL-1β and TNFα 
levels, demonstrating that PI sites were associated with a significant increase 
in their levels compared to healthy implants. IL-1β and TNFα are the two most 
important cytokines in osteoclast formation and bone resorption. IL-1β is 
mainly produced in macrophages and regulates the degradation of 
extracellular matrix components of the plasminogen system and collagenase 
activity in inflammation and wound healing. It has been shown that inhibition 
of IL-1β reduces tissue breakdown and the progression of tissue inflammation 
(Delima and Van Dyke 2003). TNFα induces fibroblast apoptosis and 
reduction of the repair capacity of peri-implant tissue (Faot, Nascimento et al. 
2015). Statistical differences were revealed when IL-1β and TNFα levels were 
compared between healthy implant sites and PID sites. No statistical 
differences could be detected between PIM and PI (Faot, Nascimento et al. 
2015). There is limited evidence presented in published literature that other 
proinflammatory cytokines (IL-6 and IL-17) have higher levels in PI compared 
to crevicular fluid associated with healthy implants (Wohlfahrt, Aass et al. 
2014, Zani, Moss et al. 2016). Contrary to what was found with IL-1β, IL-6 
increases significantly between PIM and PI. IL-1β yielded a significant 
increase after 3 weeks of cessation of oral hygiene measures and was 
reversed to pre-experimental levels 69 days after oral hygiene measures were 
reinstated (Schierano, Pejrone et al. 2008). IL-6 links innate and acquired 
immune responses, in which it induces differentiation of activated B cells into 
antibody-producing cells as well as naïve CD4+ T cells into IL-17 expressing 
T cells when TGF-𝛽 is also present (Ghassib, Chen et al. 2019). Studies of 
experimental PIM demonstrated that TNFα and TGF-𝛽2 levels did not change 
during an experimental PIM period. IL-1β, VEGF, and TIMP-2, T. denticola 
and Prevotella intermedia showed diagnostic validation for PI in this study. IL-
1β demonstrated the most significant ability for the prediction of PI disease 
status (sensitivity: 0.73, specificity: 0.73, odds ratio: 7.71) which is a moderate 
level of accuracy. The authors concluded that a combination of the above 
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markers and microbial profiles may offer site-specific diagnosis of PID due to 
the increased sensitivity and specificity compared to individual biomarkers 
(Wang, Garaicoa-Pazmino et al. 2016). To summarize, higher IL-1β and 
TNFα levels within the PICF was found to be associated with diseased 
compared to healthy implants. While combining cytokines and other 
molecules improved the accuracy to differentiate healthy from diseased 
implant sites, the confidence remained moderate.  
2.4.3. Anti-inflammatory cytokines and chemokines   
IL-10 in PICF has been shown to be negatively correlated with peri-
implant disease (Casado, Canullo et al. 2013, Zani, Moss et al. 2016). IL-4 
and IL-8 showed no differences between health and PID (Duarte, Serrao et al. 
2016). Chemokines IL-8 and Macrophage inflammatory protein-1α (MIP-1α) 
were higher in diseased sites (Hall, Pehrson et al. 2015, Bhavsar, Miller et al. 
2019).  
2.4.4. Bone loss markers 
Since RANKL and OPG are key factors regulating bone metabolism, it is 
likely they are involved in alveolar bone destruction in PI (Arikan, Buduneli et 
al. 2008). However, the majority of studies failed to identify any significant 
differences in the levels of bone metabolism markers between healthy and PI 
sites (Dursun and Tozum 2016). Soluble RANKL and OPG levels were 
evaluated in 84 samples of PICF from implants showing different peri-implant 
tissue clinical conditions without demonstrating any correlation between these 
levels and the studied clinical outcomes (Monov, Strbac et al. 2006). 
However, one study demonstrated the presence of OPG in 79% of the 
PICF samples and showed a significant positive correlation between BOP, 
while sRANKL was only detected in 12% of PICF samples and did not show 
any positive correlation with clinical inflammation (Arikan, Buduneli et al. 
2008). Another study compared the levels of C-telopeptide pyridinoline cross 
linkage of type I collagen (ICTP), sRANKL and OPG in PICF (Arikan, Buduneli 
et al. 2011). The results demonstrated “an increase in total amount of ICTP 
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and OPG in the PI group when compared to the healthy group. However, 
sRANKL was not significantly different between the healthy implant and 
diseased implant groups”. Alternatively, another report showed “significantly 
higher levels of sRANKL, OPG and RANK in PI sites compared to healthy 
implant sites” (Rakic, Lekovic et al. 2013). However, OPG/sRANKL ratio 
demonstrated no significant difference between the healthy and diseased 
implant groups. Osteocalcin, osteopontin and osteonectin proteins are related 
to bone remodeling. There were no significant differences in PICF 
osteocalcin, osteopontin and osteonectin total amounts between healthy 
controls, peri-implant mucositis and peri-implantitis groups in one recent study 
(Cakal, Efeoglu et al. 2018). 
An interventional trial assessed the effects of mechanical anti-infective 
therapy on the levels of TNFα and OPG/RANKL ratio in healthy implant and 
PI sites (Duarte, de Mendonca et al. 2009). The results demonstrated 
significantly higher levels of TNFα in PI sites when compared to healthy sites. 
OPG/RANKL ratio was shown to be low in healthy sites compared to PI sites. 
After mechanical anti-infective therapy, TNFα levels were significantly 
reduced in treated diseased sites and reached the same level as in healthy 
control sites at 3 months post therapy. In summary, bone metabolism markers 
in PICF cannot reliably differentiate healthy vs diseased implants.  
2.4.5. Enzymes 
Certain enzymes in PICF, such as cathepsin K and MMPs, were heavily 
investigated. Cathepsin-K (CatK) is a cysteine protease that is highly 
expressed by osteoclasts. Its main function is hydrolyzing the extracellular 
bone matrix proteins. CatK was shown to be elevated in GCF from chronic 
periodontitis sites compared to healthy sites. CatK is a known marker of bone 
turnover due to its key role in remodeling and cartilage breakdown in bone by 
hydrolyzing extracellular bone matrix proteins. CatK is highly and quite 
selectively expressed in active, resorbing osteoclasts (Almehmadi and 
Alghamdi 2018). This suggests its role in the pathogenesis of PI. CatK levels 
were evaluated in PICF to assess the levels of CatK in healthy implants and 
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PI in order to correlate these findings with clinical parameters. Some 
investigations showed a positive correlation between clinical parameters of PI 
and levels of CatK (Strbac, Monov et al. 2006, Yamalik, Gunday et al. 2012) 
while others concluded that CatK showed no differences between the healthy 
and diseased implant groups (Hall, Pehrson et al. 2015).  
MMP upregulation has been associated with irreversible peri-implant 
connective tissue destruction (Dursun and Tozum 2016). One suggested 
reason for MMP upregulation is polymorphism in the promoter region of MMP-
8 which explains varied responses between different individuals who have the 
same disease category (Ghassib, Chen et al. 2019). During the initiation and 
course of inflammatory responses in PI, proinflammatory mediators including 
MMP-8 are up-regulated in affected tissues and present in PICF (Sorsa, 
Tervahartiala et al. 2011). IL-1β and TNFα both induce the synthesis and 
secretion of MMP-8, which in turn, cleaves the triple helix of collagen and 
collectively degrade the extracellular matrix (Ghassib, Chen et al. 2019). 
Similar to what was found in periodontitis, there is moderate evidence in the 
literature showing high MMP-8 levels in PI compared to healthy implant sites 
(Ma, Kitti et al. 2000, Arakawa, Uehara et al. 2012, Basegmez, Yalcin et al. 
2012, Ramseier, Eick et al. 2016, Ghassib, Chen et al. 2019). MMP-8 is a 
promising biomarker as an early signal of peri-implant inflammation 
(Basegmez, Yalcin et al. 2012).  
Another investigation reported a positive correlation between MMP-8, PI, 
and BOP in both GCF and PICF (Ramseier, Eick et al. 2016). The authors 
concluded that “increased levels of MMP-8 and IL-1β in PICF or GCF may be 
associated with inflammation around teeth and implants. Other clinical trials 
demonstrated that MMP-8, MMP-9 and MMP-13 (also known as Collagenase-
2, Gelatinase B and collagenase-3, respectively) in PICF were associated 
with more bone loss around diseased implants indicating that MMP-8 could be 
a promising biomarker for peri-implant osteolysis” (Ma, Kitti et al. 2000, Ma, 
Kitti et al. 2003). However, a different trial concluded that MMP-8 did not 
reveal a meaningful difference to differentiate PI from healthy implants (Wang, 
Garaicoa-Pazmino et al. 2016). A summary of the commonly investigated and 
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promising peri-implant crevicular fluid biomarkers are shown in table 2. In 
conclusion, MMP-8 is commonly investigated in PICF and high levels of this 
enzyme may be useful in the diagnosis of peri-implantitis, however, the 
literature includes contradictory reports and further research is needed.   
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2.5. PICF biomarkers: Chair-side diagnostic tests, Limitations 
2.5.1. Chair-side diagnostic tests 
If a definitive diagnosis for PI or PIM can be made using a test with high 
validity, then a reasonable question would be, if the test is feasible and if the 
test can predict progressive PI. Clinicians seek an easy, accurate, 
inexpensive and time effective test. Most diagnostic tests in dentistry are 
performed in a clinical setting at the dental chair. A chair-side test for the 
diagnosis of PID would also be valuable if it can predict the risk of disease 
progression at an implant site.  
2.5.2. Limitations of studies 
(A) Lack of a Standardized Definition of Peri-Implantitis. 
The conflicting results of the above studies may be due to differences in 
study design, material and methods utilized, such as sample collection, 
processing and assay sensitivity. Meta-analyses in PICF biomarkers are 
scarce due to heterogeneity between studies in PI diagnosis criteria. The 
2017 World Workshop hopes to utilize their PI definition criteria in future 
clinical and research settings (Renvert, Persson et al. 2018). If some studies 
set their PI definition as radiographic bone loss of 3 mm while other studies 
had a 2 mm cut off, then the PICF results of these investigations may not be 
accurately combined and analyzed. There is a wide range of different 
definitions regarding peri-implant mucositis and peri-implantitis that were 
employed in the included investigations. The definition of peri-implantitis 
varied over time, mainly from more permissive to stricter inclusion criteria. In 
the light of the new definition of peri-implantitis by the 2017 World Workshop 
(Berglundh, Armitage et al. 2018, Renvert, Persson et al. 2018), some of the 
reviewed studies may have included cases of peri-implant mucositis in the 
group of peri-implantitis. Such misdiagnosis of peri-implantitis and inclusion of 
cases of peri-implant mucositis may affect the results of studies on PICF.  
(B) Predictive Value of Biomarkers 
  
 18 
The majority of PICF studies assessed only a few cytokines, enzymes or 
pathogens to correlate them with peri-implant diseases. Most studies lacked 
data on sensitivities and specificities to biomarkers in PICF; hence the 
probability of false positive or false negative results could not be calculated. 
PICF biomarkers analyzed individually have shown mixed results or low 
sensitivity and high specificity values, which may weaken the biomarker’s 
disease predictive value. On the other hand, biomarkers of periodontal 
disease progression in GCF alone (MMP-8, MMP-9, Osteoprotegerin, C-
reactive Protein and IL-1β) provided low sensitivity and high specificity values 
of 23% and 95%, respectively (Kinney, Morelli et al. 2014). It is noteworthy 
that, combined with plaque pathogens, GCF biomarkers demonstrated the 
highest positive and negative predictive values of 73% and 70%, respectively 
(Kinney, Morelli et al. 2014). Similarly, selected PICF-derived biomarkers of 
periodontal tissue inflammation, matrix degradation/regulation, and alveolar 
bone turnover/resorptive molecules combined with a site-specific microbial 
profile may be used to diagnose peri-implant diseases (Wang, Garaicoa-
Pazmino et al. 2016). Another multi-biomarker approach presented a 3-
biomarker model (IL-17, IL-1ra and VEGF) distinguishing healthy implant 
PICF from PID subjects with high validity (AUC: 0.90) (Zani, Moss et al. 
2016).  
(C) Potential Confounders Were Not Segregated 
Some reports failed to discuss important data, such as the general 
periodontal health in their subjects, smoking habits, systemic confounders, 
and other related criteria which may influence the levels of cytokines in PICF. 
Smoking may be an important confounder because it may affect the PICF 
volume and cytokine levels. Only a few studies excluded smokers. Other 
potential confounders may include a history of periodontitis and gingival 
phenotype. A retrospective study that analyzed risk factors for PID identified 
three predictors for PIM: history of treated periodontitis, absence of regular 
supportive peri-implant maintenance, and use of a bone graft (Atieh, Pang et 
al. 2019). The same investigation also identified three predictors for PI: 
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smoking, absence of regular supportive peri-implant maintenance and 
placement of ≥2 implants.  
(D) Sampling Techniques Were Not Standardized 
Standardization of PICF sampling is relevant due to the atypical 
morphology of the implant prosthesis. The insertion of different paper strips, 
cones, membranes or other devices would be technique sensitive and may 
offer misleading results. Biomarker concentration in the collected PICF may 
be adjusted for the collected volume due to the higher volume in inflamed 
tissues. This controversial confounder was rarely discussed in PICF studies.  
(E) Longitudinal Studies Were Lacking 
Biomarkers are not necessarily present in a single moment of PICF 
collection due to several systemic or local factors. Most studies were cross-
sectional which leads to another limitation. Due to a cyclic progression of peri-
implant diseases, the immune-inflammatory event biomarkers responsible for 
tissue breakdown may not always be active in cross-sectional studies with a 
single moment of fluid collection Dursun and Tozum (2016). Thus, studies on 
bone markers are often inconclusive despite bone loss is one of the main 
features of peri-implantitis. Very few longitudinal studies sampled implants 
over time. Some were intervention trials, sampling the diseased implants 
before and after therapy. Results showed that clinically stable treatment 
outcomes of peri-implantitis are associated with lower levels of putative 
pathogens total bacterial load and with reduction of IL-1β, IL-6, and VEGF 
levels in PICF (Renvert, Widen et al. 2017). Longitudinal studies may confirm 
the concentrations of biomarkers at specific sites and would theoretically 
show the shifts of such concentrations in diseased implants over time. These 
longitudinal investigations may aide in presenting biomarkers that predict the 
shift from health to disease or predicting the deterioration of a diseased 
implant. The validity of predicting PID is still in its infancy. 
In summary, limitations of past studies include: (1) lack of a homogenous 
definition of peri-implant health and disease, (2) lack of discussions on the 
predictive value of biomarkers, lack of segregation of potential confounders 
such as systemic diseases, smoking and a history of periodontitis, (3) different 
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sampling techniques and (4) the lack of longitudinal studies that sampled 




2.6. Omics; diagnosis and prediction of future disease progression  
2.6.1. Proteomics and Metabolomics 
The protein composition of GCF may reflect the pathophysiology of 
periodontal diseases. Protein profiles of GCF obtained from healthy 
individuals may potentially serve as a reference for identification of 
biomarkers of periodontal diseases by proteome analyses (Barros, Williams et 
al. 2016). The same may be attempted for peri-implant disease and health. A 
recent report demonstrated that a specific PICF proteomic profile associates 
with active peri-implantitis process and implant loss compared to the 
proteomic profile of healthy implants (Esberg, Isehed et al. 2019). 
Omics involves the characterization of biomolecules and includes fields 
such as genomics, epigenomics, transcriptomics, proteomics, and 
metabolomics. Multi-omics may integrate several of these methods to reach a 
more definitive analysis of complex biological processes. This can pin-point 
relevant biomarkers which may be used to define disease and physiology. 
The multi-omics approach showed that “a combination of data types (marker 
gene analysis, metagenomics, and metabolomics) provided rich and 
complementary insights into the analysis of chronic periodontal disease 
around natural teeth” (Califf, Schwarzberg-Lipson et al. 2017). Future 
directions may utilize the multi-omics approach to identify biomarkers in PI. 
However, to our knowledge, there are no studies demonstrating metabolomic 
research in peri-implant disease or physiology.  
Metabolomic analysis (a comparative analysis of metabolome levels 
between samples) that measure small degradation molecules associated with 
host and bacterial metabolism show promise (Barros, Williams et al. 2016). 
Metabolite functions include metabolism and energy storage, as well as other 
functions in cell-to-cell signaling, metal acquisition, and virulence 
(Vinayavekhin, Homan et al. 2010, Vinayavekhin and Saghatelian 2010). 
Mass spectrometry and nuclear magnetic resonance spectroscopy can be 
used to both identify and quantify chemicals from complex mixtures such as 
PICF. This particular approach is now being exploited to characterize the 
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metabolomes of many different biological samples in what is called 
quantitative metabolomics or targeted metabolic profiling (Wishart 2008). 
Metabolomics offers unique insights into small molecule regulation and 
signaling in biology. Cancer-specific signatures have been shown to be 
embedded in saliva metabolites (Sugimoto, Wong et al. 2010). Identification of 
a molecular signature for periodontitis using unbiased metabolic profiling 
could allow identification of biomarkers to assist in the diagnosis and 
monitoring of periodontal disease (Barnes, Kennedy et al. 2014). Untargeted 
metabolomics is the relative quantitation of a broad range of metabolites, both 
known and unknown, in different samples (Vinayavekhin, Homan et al. 2010, 
Vinayavekhin and Saghatelian 2010). This untargeted approach allows the 
discovery of unknown biomarkers without bias (the need to choose a certain 
substance beforehand) to correlate it with PI. These potential biomarkers may 
be investigated in longitudinal trials which can assist in the prediction of future 
disease progression.  
The metabolome consists of the final products of metabolic activities 
within a living system. These molecules belong to different compound 
classes, such as amino acids, peptides and organic acids. The goal of 
metabolomics is to map the specific metabolites which are unique for each 
condition in a living system. The concentrations of these metabolites are the 
result of the process of gene expression, protein activity and the environment 
(Razzouk and Teixeira 2010). A database of the human metabolome has 
been created (Human Metabolome Database, HMDB) and may be compared 
to the bacterial metabolome in PICF. In summary, metabolomic techniques 
incorporate the influence of environmental factors along with host 
susceptibility (Razzouk and Teixeira 2010), therefore, metabolomics may fill 




3. HYPOTHESIS AND AIM 
Diagnosing peri-implant diseases using periodontal probing and 
radiographs may be inaccurate and only provides a historical record of past 
disease rather than current disease activity. Developing biomarker 
technologies may offer possibilities in diagnostic and prognostic application. 
As studies show the increasing prevalence of peri-implant diseases, 
increasing diagnostic and predictive accuracy may have a significant impact 
on dental care. Promising directions include the use of untargeted 
metabolomics in longitudinal trials to identify a unique set of biomarkers in 
PICF. Such a trial may also be able to determine the biomarkers’ validity to 
diagnose peri-implantitis and predict which patients and which implants may 
be at risk of disease progression.  
 
We hypothesize that the simple metabolites in peri-implant crevicular fluid 
(PICF) are diagnostic of peri-implantitis and are predictors of peri-implant 
disease progression.  
 
We aim to define the unique set of metabolites in the PICF that establish 






4. MATERIAL AND METHODS 
 
4.1 Study Design 
Peri-implant crevicular fluid and salivary samples were collected from 
subjects with peri-implantitis as well as healthy implant controls at baseline 
and at six-month intervals for a total of 24 months. Clinical and radiographic 
examinations were also performed at baseline and each recall to obtain 
information regarding clinical indicators of peri-implant conditions. Peri-implant 
crevicular fluid and salivary samples were analyzed using nuclear magnetic 
resonance (NMR) spectroscopy. The study was approved by the Institutional 
Review Board at the University of Minnesota (Study number: 1511M79922). 
In this study, samples were collected from 71 implant subjects with a total of 
151 implants.  
 
4.2 Patient Selection, Inclusion and Exclusion Criteria 
Diseased implants were diagnosed with PI if they showed at least one site 
around the affected implant with a pocket depth ≥ 6 mm and ≥ 3 mm of 
radiographic bone loss (RBL) measured from the implant-abutment interface 
(IAI) to the first bone-to-implant contact. Control healthy implants must exhibit 
healthy peri-implant tissues (PD ≤ 4 mm and RBL ≤ 2 mm from implant 
abutment interface). This definition intended to avoid overlapping between 
diseased and healthy sites due to measurement errors. Test and control 
subjects must be in good general health. Smoking habits were noted. 
Exclusion criteria include: 1) uncontrolled systemic disease, such as diabetes; 
2) systemic antibiotic use within the past 3 months; 3) unable to provide 
consent; and 4) history of periodontal treatment or local antibiotic use in the 
past 12 months.   
 Subjects were selected among volunteers from patients presenting for 
treatment to the Graduate Periodontology Clinic at the University of Minnesota 
School of Dentistry from April 2015 to November 2018. Individuals who 
fulfilled the inclusion criteria were invited to participate in this study. The aim 
and the procedures of the study were discussed, and all patients signed a 
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consent and Health Insurance Portability and Accountability Act (HIPAA) form 
in accordance with the Declaration of Helsinki.  
 The first 3 recruited subject samples were eliminated due to sampling 
errors. The remaining subject pool (n=68) underwent further elimination of 
samples having errors such as pus or bleeding on the membrane, duplicates 
or missing NMR data output, 130 implant samples remained (n=61). 59 
healthy implants (bone loss <2mm; PD £4mm; n=33) and 33 diseased 
implants (bone loss ≥3mm; PD ≥6mm; n=26) were statistically analyzed. The 
“other” group, (bone loss ≥ 2mm and <3mm; PD >4mm and < 6mm) contained 
38 implants and was not included in the cross-sectional analysis as the 
implants did not meet the healthy nor diseased definitions yet were included in 
the longitudinal component to monitor possible future disease. Sampling, 
along with clinical and radiographic examinations were performed at 6, 12, 18 
and 24 months. Only 47 patients (112 implants) were sampled longitudinally. 
Metabolomic profiles of untreated deteriorating implants that demonstrated 
progressive radiographic bone loss of > 1mm within a 6-month interval 
(Progressors: n=6) were compared to untreated diseased-non-progressing 
implants (n=8) and to healthy implants (n=26) which did not deteriorate 
throughout the trial duration. 
 
4.3 Clinical Examination 
 Subjects seen for initial examination were assessed with a complete 
oral exam and clinical periodontal measurements. A Michigan-O probe with 
Williams markings color-coded probe 1-2-3-5-7-8-9-10 mm (CP-10 - Hu-
Friedy) used with light to moderate pressure into the sulcus around implants 
to measure PD (free gingival margin to base of the pocket). BOP was noted 
with 3 categories: 1 absent; 2 pinpoint bleeding; 3 profuse bleeding and 
determined 30 seconds after probing of the site. Plaque was noted as absent 
or present by sliding the periodontal probe supragingivally across each one of 
the 6 sites per implant. All the implants that were PICF-sampled and clinically 
examined were assessed with intraoral non-standardized peri-apical 
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radiographs taken at 6, 12, 18 and 24 months to monitor bone levels around 
those implants over time.  
 
4.4 Examiners and Calibration 
 Initial and periodic examinations and sample collections were carried out 
by calibrated examiners (i.e., periodontology residents). Radiographic bone 
loss measurements were carried out by Dr. Hatem Alassy. Calibration of 
residents was carried out annually.  
 
4.5 Sample Procurement 
 Subjects were sampled at least 2 weeks but no later than 8 weeks 
after their initial periodontal examination, and before periodontal treatment is 
rendered. Each test individual was sampled at the deepest site of each 
implant affected by PI. Deep sites around test implants must have PD ≥ 6 
mm. Each subject was sampled at 1 site of each implant to a maximum 4 
implants per patient. Shallow sites around healthy implants in test and control 
individuals must be have PD ≤ 4 mm.   
The sites were isolated and sampled individually. Each site was isolated 
with a cotton gauze and dried using a light air stream directed away from the 
sulcus and towards the coronal aspect of the implant’s crown. Any 
supragingival plaque was removed using a curette, with care not to touch the 
free gingival margin or push supragingival plaque subgingivally. A 4 mm 
diameter 5-micron porous silver metal membrane was inserted into the pocket 
at each implant site with cotton pliers. The membrane was completely 
inserted into the sulcus/pocket until minimal resistance was felt. Using a timer, 
the membrane is left in place for 30 seconds. Any signs of contamination from 
blood or saliva was noted.   
A saliva sample was also collected. Patients were asked to swallow 
excess saliva before placing the membrane on the dorsal side of the tongue 
for 30 seconds. All membranes were then placed in a pre-chilled Eppendorf 
tube containing a standardized buffer solution that had been kept on ice. The 
membranes were completely immersed in the buffer solution. Samples must 
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be labeled with (i) Subject ID; (ii) Implant site number (US standard); (iii) 
Location of sampling site around the implant; (iv) Health status of the site (Di 
{= deep implant site} or Si {= Shallow implant site}).   
The Eppendorf tubes were vortexed to ensure full submersion of 
membranes into the buffer and centrifuged at 16,000 RPM’s for 30 seconds. A 
micropipette was used to extract the supernatant while leaving the silver 
membrane behind. The supernatant was transferred into a new 2mL 
Eppendorf tube which is then stored at -80°C. The silver membranes were 
discarded within the original Eppendorf tube. Samples were removed from 
storage and thawed prior to being transferred from the Eppendorf tube to 
individual 1.7 x 103.5mm borosilicate tubes, SampleJet-cat#Z106462 – 
Bruker – Germany, via the aid of long gel-loading pipet tips, Sorenson- 
cat#13810, and refrigerated at ~5°C until NMR analyses were performed at 
the University of Minnesota NMR Center.   
 
4.6 NMR analysis 
Proton NMR analysis is performed at the Minnesota NMR center utilizing 
a Bruker Advance III 700-MHz spectrometer equipped with a 1.7mm 
cryogenic probe and a Sample Jet refrigerated sample changer. All 1,020 
samples were analyzed in NMR over 9 batches of ~110 each from 2016-2020. 
A gradient-enhanced two-dimensional total correlation spectroscopy (2D 1H-
1H TOCSY) pulse sequence with water suppression by excitation sculpting 
using 32 transients and 128 increments and a 7,000 Hz spectral width in each 
dimension was utilized.  
 
4.6.1 Quantification of Metabolomic Profiles using NMR 
 2D NMR profiles were constructed by overlaying the 1D NMR sample 
spectra with that of the buffer control spectra. Opensource “rNMR” and 
“Chenomx” software were used to process the 2D NMR data, and 329 regions 
of interest (ROI) were manually defined around signals of cross-peaks which 
were based on Total Correlation Spectroscopy (TOCSY) data from public 
databases, Madison-Qingdao Metabolomics Consortium Database (MMCD) 
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and Human Metabolome Database (HMDB). ROIs were not defined on cross-
peaks that appeared in the spectra for the buffer control samples. A review of 
the literature was performed to develop a list of metabolite identities 
associated with biochemical pathways suspected to play a role in 
periodontitis, since PI metabolomic data was lacking in the literature. This list 
was then used to identify and refine the manually defined ROIs resulting in 62 
regions. This refinement allowed for a reduction of ROIs which encompassed 
overlapping signals from multiple metabolites. The Human Metabolome 
Database (HMDB) was used to label the metabolites. The maximum intensity 
for each ROI was then recorded to a spreadsheet and integrated with the 
corresponding clinical data forming a peak intensity table. Identification and 
assignment of specific metabolites was based on the two protons which most 
accurately matched and represented this metabolite. These proton 
resonances were then labeled as “metabolite.1” and “metabolite.2”, referring 
to the intensity of each proton measured by NMR. This trial identified 36 
metabolites to be studied.  
 
4.7 Statistical analysis 
 
Demographic analysis was performed using chi square test, ANOVA and 
Student’s t-test. Metabolomic statistical analysis of data was performed using 
the web-based MetaboAnalyst 4.0 and 5.0 software suite 
(https://www.metaboanalyst.ca), (Chong, Wishart et al. 2019). The peak 
intensity table data was uploaded, filtered using interquartile range, 
normalized by median, log transformed and auto scaled. A principal 
component analysis (PCA) approach was used to test for the association 
between disease status (PD, RBL) and the top principal components (PCs). In 
metabolomics, PCA is used as a graphical representation for identifying 
patterns (Figure 1A). PCA is unbiased, since it ignores class labels while 
finding the variance in a dataset (Ozeki, Nozaki et al. 2016). Partial least 
squares discriminant analysis (PLS-DA) was then used to detect variable 
importance in projection (VIP) scores and estimate the predictive ability (Q2) 
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using 10-fold cross validation. The VIP score is “a weighted sum of squares of 
the PLS loadings that considers the amount of explained Y-variance of each 
component” (Chong, Wishart et al. 2019). This score identifies and ranks the 
foremost metabolites which appear to separate the groups. The higher the 
score the metabolite shows, the more important this metabolite is in the 
separation between the tested groups.  
Variable selection using Least Absolute Shrinkage and Selection Operator 
(LASSO) was used to determine frequencies of the selected metabolite. 
LASSO is a regression analysis which enhances the accuracy of the model 
being tested. Ten-fold cross-validation was performed on LASSO to yield an 
unbiased estimate of prediction error so that the best number for markers 
could be selected. This analysis offers the best (and least) number of 
covariates (metabolites in this case) to be used as predictors between the 
groups. A pattern search using the “Pattern Hunter” feature in MetaboAnalyst 
was performed. This analysis helps in the identification of metabolites 
showing a particular pattern of change similar to one chosen metabolite. This 
pattern-matching method demonstrates the metabolites most likely and least 
likely to match the concentrations of another metabolite. The resulting image 
shows both positively correlated and negatively correlated compounds 
displayed in a bar graph.  
Student’s t-test was performed for metabolite levels between specified 
groups to detect significant features using 0.05 as a cut-off P-value. We 
performed classical univariate receiver operating characteristics (ROC) curve 
analysis to calculate area under the curve (AUC) as well as their 95% 
confidence intervals, to compute optimal cutoffs for any given feature, as well 
as to generate performance tables for sensitivity, specificity, and confidence 
intervals at different cutoffs.  
A good biomarker should have high sensitivity (a positive result when the 
disease is present) and high specificity (a negative result when the disease is 
not present). The sensitivity and specificity scores are usually shown as a 
percentage, for example, a sensitivity of 90% means that this biomarker test 
correctly identified 90% of samples (true positives) which actually had disease 
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but missed 10% of diseased samples. ROC curve analysis is used to describe 
the combination of both sensitivity and specificity of a certain test’s 
performance in one chart. This diagram charts the true positive rate (y-axis 
{sensitivity}) against the false positive rate (x-axis {1-specificity}). If the 
specificity of a biomarker is 90% then this means that this marker correctly 
identified non-disease status 90% of the time and falsely identified 10% of the 
non-diseased samples as diseased. The x-axis of the ROC chart designates 
the specificity of the biomarker subtracted from 1. Therefore, a high specificity 
of 90% will be charted on the x-axis as 0.1 (1 – 0.9 = 0.1) indicating a low 
false positive rate. The best possible biomarker predictive value would be 
demonstrated as an optimal point on the upper left corner of the graph which 
indicates 100% sensitivity (1.0 true positive rate) and 100% specificity (0.0 
false positive rate). The ROC AUC scores range between 0.5 – 1. The closer 
the biomarker’s AUC analysis score is to 1.0, the more accurate this 
biomarker is. An AUC score value of 0.5 (along the diagonal line from lower 
left to upper right corners) indicates that there is no predictive value for this 
biomarker and that its assessment is not better than random. A value of 0.9 or 
more is considered excellent in accuracy while a value of 0.8 – 0.9 
demonstrates good accuracy for this biomarker and a value of 0.7 – 0.8 is fair. 
However, a value of 0.6 – 0.7 is considered poor while a value between 0.5 – 
0.6 is considered a failed marker (El Khouli, Macura et al. 2009).  
We manually selected a combination of features to create a biomarker 
model that showed a higher AUC value than any single feature. Hierarchical 
clustering using the Euclidean distance measure and Ward algorithm was 
performed on the top 15 significant features (p<0.05) for visualization of the 
most contrasting patterns between the diseased and healthy groups.  
R software is freely available, cross-platform compatible, and open 
source. Chenomx software fits 1D NMR data using reference spectra from a 
database.  Figure 1B shows 1D data from one sample (black line), 
overlaid with the database spectra of lysine-related compounds in Chenomx. 
There is overlap between all compounds. Chenomx was used in generating 
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assignments, along with the HMBD and MMCD 2D NMR databases. The 




Figure 1.  Metabolites around implants segregate from the metabolites 
in saliva and in buffer control samples. (A) Principal Component Analysis 
of metabolites comparing implants (red) vs saliva (blue) vs buffer controls 
(green). The quantity of metabolites in the PICF of all implants explain most of 
the variance between groups. (B) 1D data from one sample (black line), 
overlaid with the database spectra of lysine-related compounds in Chenomx 
software. There is overlap between compounds. The metabolites are present 
at very low levels which makes them difficult to fit, and the glycerol 





samples drowns out the signals that would make it easier, for example, to 




PICF samples which makes them difficult to fit, and the glycerol 
contamination (large signals around 3.8 in the spectrum in Figure 1B) in a 
number of samples drowns out the signals that would make it difficult, for 
example, to differentiate alanine from lysine. 
After comparisons in a cross-sectional manner, the same analyses were 
performed for longitudinal comparisons. Longitudinal assessments were 
performed for sampling time-points of 6, 12, 18, and 24 months. For each 
time-point, clinical data was used to identify sites demonstrating a significant 
increase in RBL loss (at least 1mm). The metabolite profiles for each of these 
sites were compared to those of sites which are unchanged over the same 
duration. These unchanged sites are either healthy or diseased implants 
which did not progress (< 0.5mm RBL change). ANOVA-posthoc analysis was 









5.1 Demographic data: Frequency distributions of variables  
71 persons with 151 functioning implants participated. After elimination due to 
sampling errors, the remaining subject pool (n=68) included 47% males and 
53% females having a mean age of 64.8 (SD= 9.8) (Table 3). Current 
smokers comprised 15% of the healthy implant group (n=4) and 12% of the PI 
group while past smokers comprised 31% of the healthy group (n=8) and 55% 
of the diseased group (n=18). 63 subjects had a periodontal diagnosis varying 
between slight to severe periodontitis. Age, gender and smoking status had 






Table 3: Subject demographics.  
 









































































5.2 CROSS-SECTIONAL COMPONENT 
5.2.1  Peri-Implantitis was Associated with A Distinct PICF 
Metabolomic Profile 
 
Metabolomics using NMR is used to discover biomarkers for diagnosis 
and prognosis of clinical conditions, and for mapping the metabolomic profile 
within a biological sample (Schirra and Ford 2017). The data is then analyzed 
to visualize patterns of metabolite intensities in correlation with a clinical 
condition (Ozeki, Nozaki et al. 2016). Unbiased methods are ideal for data 
exploration and analysis (Schirra and Ford 2017). Principal component scores 
can be plotted using PCA to identify clusters of correlated samples.  
Metabolite intensities were normalized to unit standard deviation before 
applying PCA to minimize the effect of confounders. A tight grouping among 
buffer control samples as well as saliva samples can be observed indicating a 
separation between controls, saliva and PICF metabolomic profiles (Figure 
1). While a tight grouping among implants’ healthy sites (green dots) 
compared to diseased sites (red dots) can be observed indicating that healthy 
sites share a similar metabolomic profile while diseased implants share a 
different metabolomic profile (Figure 2). The normalized spectra of 
metabolites demonstrated a significant separation between 59 healthy 
implants (RBL <2mm; PD £4mm; n=33) and 33 diseased implants (RBL 
≥3mm; PD ≥6mm; n=26). Using PLS-DA analysis, eleven metabolites had a 
variable importance in the project (VIP) score >1.5 (Figure 3), which is a 
common minimum score to identify significance based on most other studies, 
(Al-Ani, Fitzpatrick et al. 2016, Kuboniwa, Sakanaka et al. 2016, Sakanaka, 
















Figure 2: Diseased PICF metabolomic profiles are different from healthy 
samples. Score plots of Principal Component Analysis (PCA) of metabolites 
comparing diseased implants (red) and healthy implants (green) in (A) 2-
dimensional and (B) 3-dimensional figures. The quantity of metabolites in the 
PICF of diseased sites explain most of the variance when compared to 
healthy implants. Tight grouping among healthy vs diseased implants can be 
observed indicating that healthy sites share a similar metabolomic profile 









Figure 3. Cadaverine.Lysine is the top metabolite showing 
separation between diseased and healthy implant samples.  Variable 
importance in projection (VIP) score ranks the top 15 metabolites (out of 35 
total) showing separation between peri-implantitis vs healthy implant groups. 
Cadaverine/Lysine coherent proton resonances shows the highest relative 
concentration in diseased vs healthy implants. Metabolites having VIP scores 




5.2.2. Specific PICF Metabolite Profiles Identified Peri-Implantitis Sites 
with Moderate Accuracy and Precision.  
 
The area under the curve (AUC) in receiver operating characteristics 
(ROC) is a robust measure for comparing metabolite performance correlating 
with PI. ROC curve analysis is used to describe the combination of both 
sensitivity and specificity of a certain test’s performance in one chart. The 
AUC scores range between 0.5 – 1. The closer the biomarker’s AUC analysis 
score is to 1.0, the more accurate this biomarker is. An AUC value of 0.5 
indicates that there is no predictive value for this biomarker. A value of 0.9 or 
more is considered excellent in accuracy while a value of 0.8 – 0.9 
demonstrates good accuracy for this biomarker while a value of 0.7 – 0.8 is 
fair. However, a value of 0.6 – 0.7 is considered poor while a value between 
0.5 – 0.6 is considered a failed predictive biomarker.  
In univariate ROC curve analysis, Cadaverine/Lysine coherent proton 
resonance  shows the highest validity in correlating with PI, AUC= 0.76 (95% 
CI 0.658-0.855, t-statistic= 4.39, p=0.00003) (Figure 4) compared to healthy 
implants while alpha-ketoglutarate  was significantly associated with healthy 
implants, AUC= 0.706 (95% CI 0.593-0.819, t-statistic= -3.13, p= 0.002) 
(Figure 5).  The PICF volume in healthy and in disease sites did not 
contribute to the difference among metabolites due to effective normalization 
of the data. This is corroborated by the assessment of Tyrosine where the 
ROC analysis as not correlated with diseased or healthy implants even 
though the volumes of PICF were presumably different in health versus 







Figure 4: Cadaverine/Lysine shows high accuracy for the prediction 
of diseased implants. (A) ROC analysis curve for potential biomarkers 
demonstrate that Cadaverine/Lysine was significantly correlated with peri-
implantitis AUC=0.76; 95% CI 0.658-0.855 (blue band). The solid red dot 
indicates the optimal cutoff with the associated sensitivity and specificity 
values. (B) Box-and whisker plot showing the distribution of abundance 










Figure 5: Alpha-Ketoglutarate shows high accuracy in the prediction 
of a healthy implant status. (A) ROC analysis curve for potential biomarkers 
demonstrate that Alpha-Ketoglutarate was significantly correlated with healthy 
implants AUC=0.706; 95% CI 0.593-0.819 (blue band) p= 0.002. (B) Box-and 
whisker plot showing a higher distribution of Alpha-ketoglutarate.2 abundance 
values in the healthy compared to the diseased group. The optimal cutoff is 







Figure 6: Tyrosine did not differentiate between healthy or diseased 
implant status. (A) ROC analysis for potential biomarkers showing Tyrosine 
was not correlated with diseased or healthy implants. (B) The right-hand 
image is the box-and-whisker plot showing the distribution of abundance 
values between the two groups. This validates normalization of data and 
shows that Tyrosine’s relative concentrations were similar between healthy 






5.2.3. Combining Biomarkers Slightly Improved Predictive Accuracy 
 
The 10-fold Cross-Validation was used to generate a logistic regression 
model and calculate the performance of combining 4 metabolite resonances. 
The ROC analysis demonstrated AUC=0.789 (95% CI 0.684-0.893, p<0.01). 
Combining several metabolites may offer a higher accuracy, compared to an 
individual metabolite, in discriminating between groups. The combination of 
cadaverine.lysine.2 with methionine.2, , offered high accuracy, in 
discriminating between healthy and diseased implants (AUC=0.81, 95% CI 
0.645-0.915, p<0.01) (Figure 7), however this combination did not drastically 
improve on the accuracy found with Cadaverine.Lysine.2 resonance alone 
having AUC= 0.76 (Table 4). Figure 8 illustrates the metabolites most likely 
and least likely to be present when Cadaverine/Lysine is present. This pattern 
search using Pearson correlation coefficient identifies metabolites showing 
either positive (pink) or negative (blue) correlation with Cadaverine/lysine. 
When Cadaverine/lysine is present in a sample then tyramine and 
putrescine/lysine were most likely to be found as well, while alpha-
ketoglutarate is least likely to be present in the same sample.  
Variable selection using Least Absolute Shrinkage and Selection Operator 
(LASSO) was used to determine frequencies of the selected metabolite 
resonance. LASSO is a regression analysis which enhances the accuracy of 
the model under study. Ten-fold cross-validation was performed on LASSO to 
yield an unbiased estimate of prediction error so that the best number for 
markers could be selected. LASSO modeling demonstrated the highest 3 
frequencies were cadaverine.lysine.2, methionine.2 and putrescine.lysine 
(100%, 70% and 60% respectively). Therefore, cadaverine.lysine.2 would be 
an adequate single predictor and combining methionine.2 or putrescine.lysine 
may or may not add significant accuracy to the prediction model.  
Since the PLS-DA model is prone to overfitting, we used cross-validation 
is to determine the optimal number of components needed to build the PLS-
DA model. PLS-DA cross-validation demonstrated that a 1-component 
measure offered a significant accuracy of 0.727 (R2=0.21, Q2=0.12) (Figure 
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9). This indicates that only one component is adequate to accurately predict 
separation between the groups. While in multivariate analysis, the average 
predictive accuracy based on 100 cross validations was 0.661 (using Random 




Table 4: Cadaverine.Lysine.2 and Alpha Ketoglutarate.2 show the 
highest positive and negative correlation with diseased implant status 
respectively. Student’s t-test demonstrating t-statistic values of the 11 
significant (p<0.05) features found in the cross-sectional component 
comparing peri-implantitis with healthy implants.    













Alanine.Lysine.2 3.2792 0.0014813 0.68105 
Tyramine.1 3.1852 0.001988 0.66872 
Alpha.ketoglutarate.
2 
-3.1304 0.0023538 0.70519 
Tyramine.2 2.9447 0.0041139 0.64766 
Methionine.2 -2.8475 0.0054587 0.65691 
Uracil.1 -2.7943 0.0063554 0.67951 
Valine.2 2.7316 0.0075855 0.6754 
 
Positive correlations indicate that a higher concentration corresponds to 
increased disease presence while negative correlations indicate that a higher 
concentration corresponds to decreased disease presence. The AUC is a 








Figure 7: Combining two metabolites offered a slightly higher 
accuracy, compared to an individual metabolite, in discriminating 
between the groups. ROC analysis curve demonstrating the combination of 
cadaverine.lysine.2 and methionine.2 was able to accurately differentiate 
between diseased and healthy implant groups, AUC=0.81, 95% CI 0.645-





Figure 8: Metabolites most likely and least likely to be present when 
Cadaverine/Lysine is present. This Pattern search using Pearson 
correlation coefficient identifies metabolites showing either positive (pink) or 






Figure 9: Cross validation for the PLS-DA correlation with peri-
implantitis demonstrating that one metabolite accurately predicts 
diseased vs healthy implant status. Cross validation is performed to find 
the optimal number of components needed to create the PLS-DA model. The 
3 common models are the sum of squares (R2), cross-validation R2 (Q2) and 
Prediction Accuracy. The most common model is Q2 which is an estimate of 
the predictive ability of the model and is calculated via cross-validation. Good 
predictions will have high Q2. The red star indicates that only one component 
(metabolite) is adequate to accurately predict separation between the 




5.3  LONGITUDINAL COMPONENT 
 
Out of the 71 subjects who entered the study, only 27 completed the 24-
month samplings. While 24 subjects were only sampled once at baseline, 13 
subjects were sampled twice, 6 subjects sampled 3 times, 14 sampled 4 times 
and 14 sampled 5 times. Some subjects missed their scheduled sampling visit 
and were subsequently sampled at the follow up visits. A total of 15 implants 
were explanted during the trial while 13 implants underwent surgical 
treatment.  
A total of 9 subjects had 13 implants that progressed > 1mm of RBL loss 
over the course of the study. Seven samples were not analyzed either due to 
sampling errors or due to the subject missing a sampling visit. While only 6 
untreated implants (in 4 subjects) were documented to have progressed > 
1mm within a 6-month interval (Table 5). Only 4 implants were documented to 
have deteriorated within 12 months and 1 implant within 18 months. Within 
the deterioration periods, peri-implant pocket depths at sampling sites either 
remained the same (n=2), became deeper (n=4) or became shallower (n=3). 
Since peri-implant pocket depths were measured by multiple examiners, the 
radiographic data were chosen to document disease deterioration because 
they were measured by only one examiner. Radiographs of one example of a 
progressing implant within a 6-month interval is shown in Figure 10.  
The healthy group included non-progressing healthy implants that 
remained healthy (< 0.5mm RBL change) at the following 6-month sampling 
(and throughout the trial period). A cut-off of 0.5mm was chosen for the 
healthy group to ensure health and stability of the implants in this group and 
to reduce the chance of including an implant which may be showing signs of 
deterioration. The diseased-non-progressing group included implants that 
remained stable (< 0.5mm RBL change) at the following 6-month sampling 
(and throughout the trial period) and that did not receive treatment either at 
the implant itself nor at the teeth/implants neighboring the implant that was 




Table 5.  Longitudinal component data table. Progressing implant 
samples at only the time point before their largest RBL loss (group A), 
untreated diseased-non-progressing and healthy implant samples from the 
time point before documented radiographic stability (group C and group B 
respectively).   
 
 
















1 UniMN005 19 A 1 4 3.25 1.15 
2 UniMN043 253 A 1 23 8.85 2.4 
3 UniMn018 343 A 3 21 3.25 2.08 
4 UniMN005 400 A 4 3 2.07 1.53 
5 UniMN064 704 A 1 3 0 5.2 
6 UniMN064 705 A 1 4 2.08 4.94 
7 UniMN019 79 C 1 3 3.30 0 
8 UniMN026 109 C 1 30 3.8 (0.35) 
9 UniMN036 177 C 1 12 5.15 0.31 
10 UniMN043 254 C 1 26 5.07 (0.39) 
11 UniMN053 420 C 1 20 4.49 (0.19) 
12 UniMN059 567 C 1 25 3.12 0.12 
13 UniMN070 999 C 3 3 5.33 (0.13) 
14 UniMN070 1002 C 3 30 5.32 (0.52) 
15 UniMN007 424 B 4 30 0 0 
16 UniMN010 42 B 1 5 0 0 
17 UniMN010 43 B 1 13 0 0 
18 UniMN014 532 B 4 3 1.3 0.5 
19 UniMN015 60 B 1 20 0 0 
20 UniMN017 68 B 1 14 1.5 (0.2) 
21 UniMN017 69 B 1 30 0 0 
22 UniMN020 83 B 1 3 1.54 (0.505) 
23 UniMN020 84 B 1 19 1.3 0.195 
24 UniMN028 116 B 1 3 0.8 (0.8) 
25 UniMN031 142 B 1 12 0 0 
26 UniMN033 155 B 1 6 0.8 (0.8) 
27 UniMN035 700 B 4 5 0 0 
28 UniMN037 189 B 1 20 0 0 
29 UniMN037 190 B 1 30 0.3 (0.3) 
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30 UniMN039 218 B 1 12 0 0 
31 UniMN039 219 B 1 14 0 0 
32 UniMN039 221 B 1 29 0 0 
33 UniMN040 482 B 2 3 0.9 (0.375) 
34 UniMN040 483 B 2 8 0.4 (0.4) 
35 UniMN040 484 B 2 13 0.7 (0.7) 
36 UniMN048 823 B 4 7 1.43 (0.13) 
37 UniMN048 824 B 4 9 2.75 (0.99) 
38 UniMN066 920 B 2 19 0 0 
39 UniMN066 919 B 2 4 0 0 











Figure 10. Non-standardized periapical radiographs of implant #23 
showing > 2mm RBL within a 6-month period. (A) Bone loss of 
approximately 7mm is measured on this peri-apical radiograph. (B) Bone loss 
of approximately 10mm is measured on a second radiograph taken 6 months 
after the first radiograph. Since periapical radiographs were not standardized 
in this trial, foreshortening and elongation must be normalized. To obtain a 
true linear RBL value we used the calculation: (relative RBL) X (actual implant 
length / relative implant length). Since patient records indicated this implant to 
be 12mm then the true linear RBL in (A) is 7.83 X 12/12.98 = 7.24mm while 








5.3.1  Each of the three groups demonstrated a distinct 
metabolomic profile  
 
The progressors group (group A; n=6; containing samples from only the 
time point of before their largest RBL loss) were compared to healthy implants 
(group B; n=26) and to diseased-non-progressors (group C; n=8). The 
metabolites levels of the three groups differ significantly as demonstrated by 
the PLSDA plot (Figure 11). The VIP score plot (Figure 12) shows the top 15 
metabolites, 7 of which have a VIP score above 1.5 demonstrating a high 
level of significance. The VIP score is a mathematical algorithm which 
determines and ranks the foremost metabolites which separate between the 
groups. This is “a weighted sum of squares of the PLS loadings that considers 
the amount of explained Y-variance of each component” (Chong, Wishart et 
al. 2019). The higher the score the metabolite shows, the more important this 
metabolite is in the separation between the tested groups. The VIP score 








Figure 11. PLSDA plot demonstrating metabolite profile separation 
between the 3 groups. Progressing implant samples from all sampling time 
points (group A in red) showed separation from healthy implant samples 
(group B in green) and compared to diseased-non-progressing implants 






Figure 12. VIP scores showing the top 15 metabolites 7 of which have a 
VIP score above 1.5 (red line) demonstrating a high level of significance. 
Progressors (group A) show high scores in proline and tyrosine while the 
healthy implants (group B) show a high level of betaine and the diseased-non-
progressing implants (group C) demonstrate high scores in biotin, alanine-





A one-way ANOVA-posthoc comparison of metabolite profiles between 
the 3 groups was performed and identified statistically significant separation in 
the molecular signatures of biotin, propionate and valine, (Table 6 and Figure 
13). Biotin was significantly associated with diseased-non-progressors 
compared to both progressors and healthy implants (p< 0.000; AUC= 0.889; 
VIP> 2.0). Propionate was significantly higher in diseased-non-progressors 
compared to healthy implants (p= 0.001; AUC= 0.87). While Valine was 
significantly correlated in both progressors and diseased-non-progressors 




Table 6. Four metabolite resonances significantly separate between the 
3 groups in the longitudinal component. One-way anova-post-hoc 
analysis. Groups A=progressors, B=healthy, C=diseased-non-progressors. 
Biotin1 and biotin2 were significantly higher in diseased-non-progressors 
compared to both progressors and healthy implants (p< 0.000). Propionate 
was significantly higher in diseased-non-progressors compared to healthy (p= 
0.001). While Valine was significantly higher in both progressors and 
diseased-non-progressors compared to the healthy group (p= 0.002). 
  
f.value p.value -log10(p) FDR Fisher's 
LSD 
Biotin.1 12.767 6.0758E-05 4.2164 0.003524 C - A; C - B 
Biotin.2 11.159 0.00016131 3.7923 0.0046781 C - A; C - B 
Propionate 7.6524 0.0016547 2.7813 0.031991 C - B 



















































Figure 13. Significant metabolites separate between progressors, 
diseased-non-progressors and healthy implants. (A) The purple dots on 
the plot are the 4 metabolites (biotin1, biotin2, propionate and valine2) 
showing statistical significance (p< 0.05) between progressors, diseased-non-
progressors and healthy implants. (B-F) Box and whisker plots shows 






significantly higher in diseased-non-progressors compared to both 
progressors and healthy implants (p< 0.000). (D) Propionate was significantly 
higher in diseased-non-progressors compared to healthy (p= 0.001). (E) 
Valine was significantly higher in both progressors and diseased-non-
progressors compared to the healthy group (p= 0.002). (F) Proline1 did not 
show statistical significance in the anova analysis, however, demonstrated 
higher means progressors followed by healthy followed by diseased-non-




5.3.2  Biotin, propionate, valine and proline significantly 
separated diseased-non-progressors from healthy implants  
 
PLSDA and VIP plots and Student’s t-tests were performed to further 
analyze the differences between groups. When the diseased-non-progressors 
(group C) were compared to the healthy group (group B); proline1 was found 
to be correlated with the healthy group (p= 0.004; AUC= 0.755; VIP> 1.8) 
(Table 7). While biotin, propionate and valine significantly correlated with the 
diseased-non-progressing implants (p< 0.002). Furthermore, such correlation 
for biotin and propionate had VIP scores > 2.0 and a Q2 predictive value of 0.2 
indicating high accuracy (Figure 14). The ROC analyses plot demonstrating 
high validity (AUC: 0.755-0.889) in separation between 5 metabolites in 
healthy implant sites compared to diseased-non-progressing implant sites 
(Figure 15). Box and whisker plots of the statistically significant (p< 0.05) 
metabolites demonstrating that biotin1, biotin2, propionate2 and valine2 are 





Table 7. Five metabolite resonances separate between Diseased-non-
progressors group vs the healthy group in this t-test. A positive t-statistic 
indicates a correlation with healthy while a negative t-statistic indicates 
correlation with diseased-non-progressors. When the diseased-non-
progressors were compared to the healthy group; proline1 was found to be 
correlated with the healthy group (p= 0.004). 
 
 
t.stat p.value -log10(p) FDR 
Biotin.2 -4.908 2.5957E-05 4.5858 0.0011591 
Biotin.1 -4.7591 3.9968E-05 4.3983 0.0011591 
Propionate -3.7989 0.00061395 3.2119 0.01187 
Valine.2 -3.3584 0.002037 2.691 0.029537 







   







Figure 14. Significant metabolites show separation between healthy and 
diseased-non-progressor groups. (A) PLS-DA plot demonstrating 
separation between metabolites in healthy (B, red) implant sites compared to 
diseased-non-progressors (C, green) implant sites. (B) VIP scores showing 
the top 15 metabolites 9 of which have a VIP score above 1.5 demonstrating 
a level of significance. (C) Cross validation chart demonstrating a Q2 






5.3.3  Progressing implants demonstrated a distinct metabolomic 
profile prior to bone loss  
 
The progressors’ samples at only the time point of before their largest 
RBL loss were identified (group A) and compared with diseased-non-
progressing implants (group C) that showed no deterioration (< 0.5mm 
change) in RBL in their following sampling visits. Since the sample size of the 
progressing implants was small (n=6), statistical significance was not 
achieved when studying these implants immediately prior their deterioration 
measured via radiographic bone loss. A PLS-DA plot comparing progressors 
(group A) with diseased-non-progressors (group C) demonstrated a tight 
grouping of metabolites separating the groups (Figure 16). High accuracy in 
the ROC analysis was demonstrated in figure 16b. Proline and 1-3-
diaminopropane were higher in the progressors with AUC= 0.917 and 0.854 
respectively. While Glucose was correlated with the diseased-non-
progressors (AUC= 0.896).  
Another PLS-DA plot comparing progressors (group A) with healthy 
implants (group B) demonstrated a tight grouping of metabolites separating 
the groups (Figure 17), yet statistical significance was not reached. However, 
high accuracy in the ROC analysis, figure 17, was demonstrated by the 
correlation of 1-3-diaminopropane with the progressors (AUC= 0.84) while 
betaine and arginine were correlated with healthy implants (AUC= 0.827 and 
0.801 respectively).  
In summary, the cross-sectional component of this study demonstrated 
that simple metabolites in PICF are diagnostic of peri-implantitis since specific 
metabolites differentiated between the healthy and diseased groups with 
moderate accuracy. These simple metabolites were namely cadaverine.lysine 
and alpha ketoglutarate. The longitudinal component of this trial mapped a 
specific metabolomic profile able to identify implants in health versus 
progressive disease versus a non-progressing disease status. Therefore, 

















Figure 15. ROC analyses and Box and whisker plots demonstrating 
good accuracy (AUC: 0.755-0.889) in separation between 5 metabolites 
in healthy implant sites compared to diseased-non-progressing implant 
sites. The blue band represents the 95% confidence interval while the solid 
red dot indicates the optimal cutoff with the associated sensitivity and 
specificity values. (A-D) Box and whisker plots of the statistically significant 
(p< 0.05) metabolites demonstrating that biotin1, biotin2, propionate2 and 
valine2 are correlated with diseased-non-progressors while, (E) proline1 was 






















Figure 16. Significant metabolites showing separation between 
progressors and diseased-non-progressor groups. (A) PLS-DA plot 
comparing progressors (group A, red) with diseased-non-progressors (group 
C, green) demonstrating a tight grouping of metabolites separating the 
groups, yet statistical significance was not reached. (B-E) High accuracy in 
the ROC analysis was demonstrated. Proline and 1-3-diaminopropane were 
higher in the progressors with AUC= 0.917 and 0.854 respectively. While 
glucose.2 and biotin.2 were correlated with the diseased-non-progressors 
(AUC= 0.896 and 0.875 respectively). The blue band represents the 95% 
confidence interval while the solid red dot indicates the optimal cutoff with the 

























Figure 17. Significant metabolites showing separation between 
progressors and healthy groups. (A) PLS-DA plot comparing progressors 
(group A, red) with healthy implants (group B, green) demonstrating a tight 
grouping of metabolites separating the groups, yet statistical significance was 
not reached. (B-D) High accuracy in the ROC analysis was demonstrated by 
1-3-diaminopropane showing correlation with the progressors (AUC= 0.84) 
while betaine and arginine were correlated with healthy implants (AUC= 0.827 
and 0.801 respectively). The blue band represents the 95% confidence 
interval while the solid red dot indicates the optimal cutoff with the associated 








6.1 Standardizing study design for peri-implantitis 
 
There was a wide heterogeneity in defining PI. We defined PI according to 
the “2017 World Workshop on the Classification of Periodontal and Peri-
implant Diseases and Conditions” (Berglundh, Armitage et al. 2018). “In the 
absence of initial radiographs and probing depths, radiographic evidence of 
bone loss of ≥3 mm and/or probing depths ≥6 mm in conjunction with profuse 
bleeding fits this definition”. Peri-implant health is defined as PD ≤5.0 mm and 
RBL <2mm, (Araujo and Lindhe 2018). Even though the probing depth 
associated with peri-implant health should be ≤5.0 mm, we preferred the cut-
off to be ≤4mm to allow for operator error. During the annual examiner 
calibration trial, exact intra-examiner and inter-examiner agreement in PD 
ranged between 60.7%-83.3% and 46%-66.1% respectively. The predictability 
increased when there was a ±1 mm leeway in measurement to be between 
97.6%-100% for intra-examiner agreement and 92.1%-99.4% for inter-
examiner agreement. When two examiners digitally measured the RBL on the 
non-indexed periapical radiographs, a paired t-test showed a significant mean 
difference in RBL calculations of 0.14mm (p < 0.03, 95% CI 0.01 to 0.28) and 
similar variance (SD=2.73) for both examiners. Only one examiner (H. A.) 
performed the RBL measurements to reduce the probability of error. A 
radiographic bone loss of at least 1.0 mm was considered as a cut-off for 
documented deterioration based on past studies recommending that “the 
clinical assessment for each implant monitors marginal bone loss in 
increments of 1.0 mm” (Misch, Perel et al. 2008, Renvert, Lindahl et al. 2012).  
 
6.2 Metabolomics allows the discovery of novel biomarkers for 




The composition of PICF may reflect the pathophysiology of PI. 
Metabolomic analysis measures small degradation molecules associated with 
host and bacterial metabolism. Metabolite functions include metabolism, 
energy storage, cell-to-cell signaling, virulence, (Vinayavekhin and 
Saghatelian 2010). Un-targeted Metabolomics using NMR spectroscopy can 
be used to both identify and quantify chemicals from the PICF in an unbiased 
technique similar to past studies evaluating saliva or gingival crevicular fluid 
around natural dentition, (Barnes, Teles et al. 2009, Barnes, Teles et al. 2010, 
Sugimoto, Wong et al. 2010, Barnes, Ciancio et al. 2011, Barnes, Kennedy et 
al. 2014, Schirra and Ford 2017, Romano, Meoni et al. 2018, Romano, Meoni 
et al. 2019, Yatsuoka, Ueno et al. 2019). This un-targeted approach allows 
the discovery of unknown biomarkers, without bias, to correlate them with PI.  
Metabolomic investigations can evaluate a large collection of metabolites, 
which contain several promising biomarkers for risk prediction, diagnosis, and 
treatment effects, and present specific markers related to the outcome of 
interest, making it useful for clinical application. General medical metabolomic 
research has investigated a variety of diseases and conditions to attempt the 
early prediction of disease progression. For example, one recent trial found 
that methionine, an essential amino acid, was elevated in plasma samples in 
patients with short survival due to endometrial cancer with, when compared to 
matched patients with long survival (Strand, Tangen et al. 2019). That study 
concluded that specific blood metabolites were associated with poor survival 
rates (prognosis) with this type of cancer. Another trial mapped a “specific 
metabolomic profile which predicts future weight gain that is an independent 
predictor distinct from several other known risk factors” (Geidenstam, Hsu et 
al. 2019).  
We identified the molecular signature of lysine in PI using unbiased 
metabolic profiling. This study found that simple metabolites may discriminate 
peri-implant health from disease. The top metabolites significantly correlated 
with PI were cadaverine, lysine, putrescine, alanine, tyramine, valine. While 
the top metabolites found correlated with implant health were alpha-
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ketoglutarate, methionine and uracil. These novel metabolites may be 
diagnostic biomarkers for peri-implantitis.  
On the other hand, in the longitudinal portion, 6 deteriorating implants 
(progressors: group A; containing samples from only the time point of before 
their largest RBL loss) were compared with healthy implants (group B; n=26) 
and with diseased-non-progressors (group C; n=8). The diseased-non-
progressing group and the healthy group included implants that remained 
stable (< 0.5mm RBL change) at their following 6-month sampling (and 
throughout the trial period) and that did not receive any treatment either on 
the implant nor the teeth/implants neighboring to it. Comparing the 3 groups 
offered a prognostic value in forecasting implant deterioration versus stability.  
The significant metabolites separating the diseased from healthy implants 
at baseline (cross-sectional component) were not the same metabolites 
showing separation in the longitudinal portion. There are two reasons why this 
might be. A) the diseased group at baseline included both progressors AND 
non-progressors, therefore the metabolomic profile is different. This trial 
demonstrated that not all diseased implants are equal because some 
progress while some are stable. Therefore, the stable (diseased-non-
progressors) implants might have been incorrectly diagnosed as diseased 
since our diagnosis relies on RBL (which may have been historic then 
stabilized) and PD (which may be transient mucositis). B) The healthy implant 
group at baseline may have also included implants which were about to 
deteriorate in the near future, thus had metabolites differing from other 
implants which remained healthy. 
 
 
6.3 Lysine, Putrescine, Cadaverine are diagnostic of peri-implantitis 
 
Decarboxylation of amino acids may yield omega-amino acids such as 
beta-alanine, gamma-aminobutyrate, and delta-aminovalerate as well as 
alpha, omega-diamines such as putrescine and cadaverine, (Wendisch 2017). 
Cadaverine is a diamine formed by bacterial decarboxylation of lysine that 
  
 77 
occurs during putrefaction of tissues. Cadaverine is almost exclusively of 
bacterial origin, (Barnes, Teles et al. 2009), while putrescine can be produced 
by both bacterial and mammalian metabolic pathways. A previous 
metabolomic study concluded that “both cadaverine and putrescine, the end-
products of amino acid degradation, were found to be up-regulated by 
periodontal disease” (Barnes, Teles et al. 2009).  
 
Lysine is an essential amino acid. Lysine degradation is related to the 
metabolic signatures of periodontal disease-associated microbial 
communities, (Sakanaka, Kuboniwa et al. 2017). Past studies link 
Porphyromonas gingivalis to “lysine-specific cysteine proteases”, which is also 
described as gingipains. Gingipains are main virulence factors with the ability 
to degrade immunoglobulins (IgA, IgG, IgM) (Butler, Veith et al. 2015). P. 
gingivalis is “a Gram-negative anaerobe considered to be a keystone 
pathogen in the development of the bacterial-associated inflammatory oral 
disease chronic periodontitis”. PI was associated with higher counts of 19 
bacterial species, including P. gingivalis (Schwarz, Derks et al. 2018). 
Metabolites most likely and least likely to be present when Cadaverine/Lysine 
is present are demonstrated in Figure 8. This grouping may be used to 
develop metabolic pathways to study the physiology of implant disease.  
 
6.4 Alpha-ketoglutarate is inversely related to peri-implantitis 
 
This study found a strong inverse correlation between PI and alpha-
ketoglutarate (α-KG), which is a key molecule in several physiologic functions 
such as the tricarboxylic acid cycle and is required in the production of type I 
collagen. Additionally, α-KG is an “immunomodulator which promotes M2 
macrophage activation and T-reg (regulatory T-cell) differentiation” (Klysz, Tai 
et al. 2015). T-reg cells and M2 macrophages are known to regulate the 
immune response and play a role in inflammation resolution and repair. A 
recent murine study found that P. gingivalis “maintains a hyperinflammatory 
state by suppressing the pathway synthesis genes of α-KG” (Yu, Ding et al. 
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2018). The same study demonstrated that “supplementation of α-KG 
dramatically restored M2 activation during P. gingivalis infection”. It was 
concluded that this metabolite may play a role in the resolution of periodontal 
inflammation.  
Since periodontal and peri-implant tissue breakdown involves 
upregulation of the immune response and destruction of Type I collagen, it is 
possible that α-KG’s absence from diseased peri-implant PICF in this study is 
a significant finding. There is a paucity of literature describing the interactions 





6.5 Proline and 1-3-diaminopropane predict future peri-implant bone 
loss while glucose, biotin, propionate, betaine and arginine predict 
implant stability 
 
The current diagnostic criteria for peri-implantitis are clinical and 
radiographic signs of inflammation and bone level loss. However, there are 
currently no prognostic methods to guide towards the most suitable 
therapeutic modality. A prognostic factor is a measurement that would 
determine the natural progression of a specific diseased implant. This 
measurement, if available, would optimize the management of the patient’s 
implant.  
Analysis of variance (ANOVA) between 3 groups in this longitudinal 
(progressors, healthy, diseased-non-progressors) displayed statistical 
significance in 3 metabolites. These simple compounds may predict the short-
term change in bone level around an implant. Biotin, propionate and valine 
exhibited a marked difference in their ratios between the groups. Biotin1 and 
biotin2 were significantly higher in diseased-non-progressors compared to 
both progressors and healthy implants (p< 0.000). Propionate was 
significantly higher in diseased-non-progressors compared to healthy (p= 
0.001). While Valine was significantly higher in both progressors and 
diseased-non-progressors compared to the healthy group (p= 0.002). 
Furthermore, PICF concentrations of proline and 1-3-diaminopropane were 
directly proportional to progressive bone loss over time, however, the 
difference did not reach statistical significance possibly due to a low sample 
size. 
Biotin, also known as vitamin B7, is an enzyme co-factor present in all 
cells. This metabolite was significantly higher in diseased-non-progressing 
implants compared to the other 2 groups. The biotin cycle “involves the 
utilization of biotin for covalent attachment to carboxylases and its reutilization 
through the release of carboxylase biotin after proteolytic degradation”. Biotin 
deficiency may lead to unfavorable conditions which may include progressive 
bone loss in the case of diseased implants.  
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Propionate (Propionic acid) is found in humans as an end-product of the 
microbial digestion of carbohydrates and contribute to significant physiological 
activities. These gut microbes include Bacteroides, Clostridium, Dialister, 
Megasphaera, Phascolarctobacterium, Propionibacterium, Propionigenum, 
Salmonella, Selenomonas and Veillonella. Propionate was significantly higher 
in diseased-non-progressors compared to healthy implants.  
Valine was significantly higher in both progressors and diseased-non-
progressors compared to the healthy group. Valine is an essential amino acid 
named after the plant valerian. It is critical for human life and has a role in 
stress and energy metabolism. This metabolite, when analyzed in the saliva, 
was found to be biomarker for pancreatic cancer in a metabolomics study 
(Sugimoto, Wong et al. 2010). Increased levels of valine were found in saliva 
samples of individuals with moderate-severe periodontitis (Liebsch, Pitchika et 
al. 2019). This amino-acid’s catabolism provides energy for bacteria and its 
pathway was found in periodontal pathogenic P. gingivalis, Prevotella 
intermedia, Eubayterium brachy.  
Other metabolites’ differences did not reach statistical difference in the 
ANOVA analysis, however, displayed high accuracy in the ROC analysis. 
Proline and 1-3-diaminopropane were higher in the progressors (AUC= 0.917 
and 0.854 respectively). While Glucose was correlated with the diseased-non-
progressors (AUC= 0.896). An AUC value of 0.9 or more is considered 
excellent in accuracy while a value of 0.8 – 0.9 demonstrates good accuracy 
for this biomarker while a value of 0.7 – 0.8 is fair. However, a value of 0.6 – 
0.7 is considered poor while a value between 0.5 – 0.6 is considered a failed 
predictive biomarker. Proline offered an excellent accuracy in predicting 
disease progression while 1-3-diaminopropane demonstrated a good 
accuracy.  
Proline is an essential component of collagen and was recently found to 
be associated with more severely affected periodontal disease in a salivary 
metabolomics study (Marchesan, Morelli et al. 2015, Bostanci, Grant et al. 
2021). Therefore, this metabolite’s association with progressive peri-implant 
disease in this study was not surprising. Additionally, 1-3-Diaminopropane 
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was associated with the progressors group compared to both other groups. 
This metabolite is a toxic monoalkylamine, however, it is present in certain 
foods such as certain mushrooms, grapes and cinnamon. It is involved in the 
arginine/proline metabolic pathways and the beta-alanine metabolism. This 
metabolite, 1-3-Diaminopropane, along with other urinary polyamines such as 
the previously mentioned putrescine and cadaverine, were previously studied 
and found to be markers of leukemia (Lee, Suh et al. 1998).  
Although statistically insignificant, levels of arginine were inversely 
proportional to progressive bone loss compared to peri-implant bone level 
stability. Arginine levels were high in both healthy (group B) and diseased-
non-progressors (group C) when compared to its low levels in the progressors 
group (group A). Arginine is an essential amino acid however adults are able 
to synthesize it in the urea cycle. Arginine and its derivatives are “key factors 
for inter-bacterial communication in periodontal microflora” (Sakanaka, 
Kuboniwa et al. 2015). “Alkali generation by oral microbes, specifically via 
arginine catabolic pathways, is an essential factor in maintaining plaque pH 
homeostasis and arginine was found to improve pH homeostasis via 





6.6 Study Limitations 
 
Metabolomics in dentistry is still in its infancy. NMR techniques by 
definition, detect hydrogen resonances which in turn are matched with known 
molecules, yet this study had overlapping of different hydrogen resonances 
which are shared by different metabolites due to the limited fluid quantity 
sampled. Future techniques may include mass spectrometry to confirm the 
findings of this study. Biomarkers are not necessarily present in a single 
moment of PICF collection due to systemic or local factors. Therefore, 
longitudinal studies may confirm the concentrations of metabolites and 
possibly show the shifts of such concentrations in diseased implants over time 
or after therapy. Unfortunately, this study lacked an adequate sample size of 
diseased and progressing implants studied over time. This is due to the fact 
that most subjects with diseased implants get treatment and therefore only a 
handful of subjects made the decision to halt any treatment for personal 
reasons. Studying progressing implants may be unethical if this criterion was 
part of the study design. Another limitation was the use of silver membrane 
discs to collect PICF. Examiners found difficulty inserting these silver discs in 
implant crevices since implant crowns typically have a concave subgingival 
profile. Figure 18 demonstrates the insertion of a pre-bent silver membrane 
into the implant’s gingival crevice. Levels of some metabolites were under the 
detection limit, which may cause bias. There were no adjustments for multiple 
comparisons, which might be a limitation. We did not adjust for potential 
confounders nor batch effects, which may affect the metabolite values. The 
subjects and implants in each group were not matched by factors such as 
age, gender, smoking, periodontal disease. The findings of the current study 
should be verified in a larger and matched patient cohort. Being a small study 
cohort, the findings would not necessarily be reflected in a similar larger trials, 
but the current study demonstrates that metabolomics is a promising future 





6.7 Future Direction 
 
This metabolomic study offers the first insight on simple metabolites 
correlating with the prognosis of peri-implantitis. The metabolomic unbiased 
methodology allowed the discovery of molecules which have never received 
focus in past PI trials. These metabolites significantly relating to peri-implant 
disease progression may prove influential in prognosis and the choice of 
therapeutic modality. Future studies may elucidate on metabolomic changes 
over time or after implant therapy. Additionally, metabolic pathway analysis of 
these relevant metabolites may explain the physiology of peri-implant disease. 
Since putative pathogens were found to remodel the host’s metabolic 
pathways and upregulate inflammatory processes, it may be possible to 








Figure 18. Insertion of a pre-bent silver membrane into the implant’s 






Peri-implant crevicular fluid (PICF) metabolites identified using proton 
NMR spectroscopy may be considered novel biomarkers using unbiased 
metabolomic profiling. These metabolomic profiles were able to discriminate 
between peri-implantitis and healthy implants as well as for early detection of 
disease progression. Lysine coherent resonances were significantly 
correlated with peri-implantitis while alpha-ketoglutarate was correlated with 
implant health. Furthermore, profiles of biotin, propionate and valine exhibited 
statistically significant differences when comparing the implants which had 
progressive bone loss over time with implants having non-progressing peri-
implantitis and with healthy implants. This study also identified the molecular 
signatures of proline and 1-3-diaminopropane in peri-implantitis progression, 
while arginine was associated with non-progressing peri-implantitis, however, 
statistical significance was not reached. Future studies may investigate the 
metabolic pathways of these metabolites associated with peri-implantitis and 
its progression to better understand its pathogenesis and biological 
mechanisms. This knowledge may assist in the diagnosis and predict the 



















Agnello, M., L. Cen, N. C. Tran, W. Shi, J. S. McLean and X. He (2017). "Arginine 
Improves pH Homeostasis via Metabolism and Microbiome Modulation." J 
Dent Res 96(8): 924-930. 
Al-Ani, B., M. Fitzpatrick, H. Al-Nuaimi, A. M. Coughlan, F. B. Hickey, C. D. 
Pusey, C. Savage, C. M. Benton, E. C. O'Brien, D. O'Toole, K. H. Mok, S. P. 
Young and M. A. Little (2016). "Changes in urinary metabolomic profile during 
relapsing renal vasculitis." Sci Rep 6: 38074. 
Almehmadi, A. H. and F. Alghamdi (2018). "Biomarkers of alveolar bone 
resorption in gingival crevicular fluid: A systematic review." Arch Oral Biol 93: 
12-21. 
Arakawa, H., J. Uehara, E. S. Hara, W. Sonoyama, A. Kimura, M. Kanyama, Y. 
Matsuka and T. Kuboki (2012). "Matrix metalloproteinase-8 is the major 
potential collagenase in active peri-implantitis." J Prosthodont Res 56(4): 249-
255. 
Araujo, M. G. and J. Lindhe (2018). "Peri-implant health." J Periodontol 89 
Suppl 1: S249-s256. 
Arikan, F., N. Buduneli and N. Kutukculer (2008). "Osteoprotegerin levels in 
peri-implant crevicular fluid." Clin Oral Implants Res 19(3): 283-288. 
Arikan, F., N. Buduneli and D. F. Lappin (2011). "C-telopeptide pyridinoline 
crosslinks of type I collagen, soluble RANKL, and osteoprotegerin levels in 
crevicular fluid of dental implants with peri-implantitis: a case-control study." 
Int J Oral Maxillofac Implants 26(2): 282-289. 
Atieh, M. A., J. K. Pang, K. Lian, S. Wong, A. Tawse-Smith, S. Ma and W. J. 
Duncan (2019). "Predicting peri-implant disease: Chi-square automatic 
interaction detection (CHAID) decision tree analysis of risk indicators." J 
Periodontol 90(8): 834-846. 
Barnes, V. M., S. G. Ciancio, O. Shibly, T. Xu, W. Devizio, H. M. Trivedi, L. Guo 
and T. J. Jonsson (2011). "Metabolomics reveals elevated macromolecular 
degradation in periodontal disease." J Dent Res 90(11): 1293-1297. 
Barnes, V. M., A. D. Kennedy, F. Panagakos, W. Devizio, H. M. Trivedi, T. 
Jonsson, L. Guo, S. Cervi and F. A. Scannapieco (2014). "Global metabolomic 
analysis of human saliva and plasma from healthy and diabetic subjects, with 
and without periodontal disease." PLoS One 9(8): e105181. 
Barnes, V. M., R. Teles, H. M. Trivedi, W. Devizio, T. Xu, D. P. Lee, M. W. 
Mitchell, J. E. Wulff, M. V. Milburn and L. Guo (2010). "Assessment of the 
  
 87 
effects of dentifrice on periodontal disease biomarkers in gingival crevicular 
fluid." J Periodontol 81(9): 1273-1279. 
Barnes, V. M., R. Teles, H. M. Trivedi, W. Devizio, T. Xu, M. W. Mitchell, M. V. 
Milburn and L. Guo (2009). "Acceleration of purine degradation by periodontal 
diseases." J Dent Res 88(9): 851-855. 
Barros, S. P., R. Williams, S. Offenbacher and T. Morelli (2016). "Gingival 
crevicular fluid as a source of biomarkers for periodontitis." Periodontol 2000 
70(1): 53-64. 
Basegmez, C., S. Yalcin, F. Yalcin, S. Ersanli and E. Mijiritsky (2012). "Evaluation 
of periimplant crevicular fluid prostaglandin E2 and matrix metalloproteinase-
8 levels from health to periimplant disease status: a prospective study." Implant 
Dent 21(4): 306-310. 
Berglundh, T., G. Armitage, M. G. Araujo, G. Avila-Ortiz, J. Blanco, P. M. 
Camargo, S. Chen, D. Cochran, J. Derks, E. Figuero, C. H. F. Hammerle, L. J. A. 
Heitz-Mayfield, G. Huynh-Ba, V. Iacono, K. T. Koo, F. Lambert, L. McCauley, 
M. Quirynen, S. Renvert, G. E. Salvi, F. Schwarz, D. Tarnow, C. Tomasi, H. L. 
Wang and N. Zitzmann (2018). "Peri-implant diseases and conditions: 
Consensus report of workgroup 4 of the 2017 World Workshop on the 
Classification of Periodontal and Peri-Implant Diseases and Conditions." J 
Periodontol 89 Suppl 1: S313-s318. 
Bevilacqua, L., M. D. Biasi, M. G. Lorenzon, C. Frattini and D. Angerame (2016). 
"Volumetric Analysis of Gingival Crevicular Fluid and Peri-Implant Sulcus 
Fluid in Healthy and Diseased Sites: A Cross-Sectional Split-Mouth Pilot 
Study." Open Dent J 10: 131-138. 
Bhavsar, I., C. S. Miller, J. L. Ebersole, D. R. Dawson, 3rd, K. L. Thompson and 
M. Al-Sabbagh (2019). "Biological response to peri-implantitis treatment." J 
Periodontal Res. 
Bostanci, N., M. Grant, K. Bao, A. Silbereisen, F. Hetrodt, D. Manoil and G. N. 
Belibasakis (2021). "Metaproteome and metabolome of oral microbial 
communities." Periodontol 2000 85(1): 46-81. 
Butler, C. A., P. D. Veith, M. F. Nieto, S. G. Dashper and E. C. Reynolds (2015). 
"Lysine acetylation is a common post-translational modification of key 
metabolic pathway enzymes of the anaerobe Porphyromonas gingivalis." J 
Proteomics 128: 352-364. 
Cakal, O. T., C. Efeoglu and E. Bozkurt (2018). "The evaluation of peri-implant 
sulcus fluid osteocalcin, osteopontin, and osteonectin levels in peri-implant 
diseases." J Periodontol 89(4): 418-423. 
Califf, K. J., K. Schwarzberg-Lipson, N. Garg, S. M. Gibbons, J. G. Caporaso, J. 
Slots, C. Cohen, P. C. Dorrestein and S. T. Kelley (2017). "Multi-omics Analysis 
  
 88 
of Periodontal Pocket Microbial Communities Pre- and Posttreatment." 
mSystems 2(3). 
Carcuac, O. and T. Berglundh (2014). "Composition of human peri-implantitis 
and periodontitis lesions." J Dent Res 93(11): 1083-1088. 
Casado, P. L., L. Canullo, A. de Almeida Filardy, J. M. Granjeiro, E. P. Barboza 
and M. E. Leite Duarte (2013). "Interleukins 1beta and 10 expressions in the 
periimplant crevicular fluid from patients with untreated periimplant disease." 
Implant Dent 22(2): 143-150. 
Chatzopoulos, G. S., K. C. Mansky, S. Lunos, M. Costalonga and L. F. Wolff 
(2019). "Sclerostin and WNT-5a gingival protein levels in chronic periodontitis 
and health." J Periodontal Res 54(5): 555-565. 
Chong, J., D. S. Wishart and J. Xia (2019). "Using MetaboAnalyst 4.0 for 
Comprehensive and Integrative Metabolomics Data Analysis." Curr Protoc 
Bioinformatics 68(1): e86. 
Costalonga, M. and M. C. Herzberg (2014). "The oral microbiome and the 
immunobiology of periodontal disease and caries." Immunol Lett 162(2 Pt A): 
22-38. 
Delima, A. J. and T. E. Van Dyke (2003). "Origin and function of the cellular 
components in gingival crevice fluid." Periodontol 2000 31: 55-76. 
Derks, J., D. Schaller, J. Hakansson, J. L. Wennstrom, C. Tomasi and T. 
Berglundh (2016). "Peri-implantitis - onset and pattern of progression." J Clin 
Periodontol 43(4): 383-388. 
Derks, J. and C. Tomasi (2015). "Peri-implant health and disease. A systematic 
review of current epidemiology." J Clin Periodontol 42 Suppl 16: S158-171. 
Duarte, P. M., A. C. de Mendonca, M. B. Maximo, V. R. Santos, M. F. Bastos and 
F. H. Nociti (2009). "Effect of anti-infective mechanical therapy on clinical 
parameters and cytokine levels in human peri-implant diseases." J Periodontol 
80(2): 234-243. 
Duarte, P. M., C. R. Serrao, T. S. Miranda, L. C. Zanatta, M. F. Bastos, M. Faveri, 
L. C. Figueiredo and M. Feres (2016). "Could cytokine levels in the peri-implant 
crevicular fluid be used to distinguish between healthy implants and implants 
with peri-implantitis? A systematic review." J Periodontal Res 51(6): 689-698. 
Dursun, E. and T. F. Tozum (2016). "Peri-Implant Crevicular Fluid Analysis, 
Enzymes and Biomarkers: a Systemetic Review." J Oral Maxillofac Res 7(3): e9. 
Eckert, M., D. Mizgalska, A. Sculean, J. Potempa, A. Stavropoulos and S. Eick 
(2018). "In vivo expression of proteases and protease inhibitor, a serpin, by 
periodontal pathogens at teeth and implants." Mol Oral Microbiol 33(3): 240-
248. 
El Khouli, R. H., K. J. Macura, P. B. Barker, M. R. Habba, M. A. Jacobs and D. 
A. Bluemke (2009). "Relationship of temporal resolution to diagnostic 
  
 89 
performance for dynamic contrast enhanced MRI of the breast." J Magn Reson 
Imaging 30(5): 999-1004. 
Elani, H. W., J. R. Starr, J. D. Da Silva and G. O. Gallucci (2018). "Trends in 
Dental Implant Use in the U.S., 1999-2016, and Projections to 2026." J Dent Res 
97(13): 1424-1430. 
Englezos, E., J. Cosyn, S. Koole, W. Jacquet and H. De Bruyn (2018). "Resective 
Treatment of Peri-implantitis: Clinical and Radiographic Outcomes After 2 
Years." Int J Periodontics Restorative Dent 38(5): 729-735. 
Esberg, A., C. Isehed, A. Holmlund and P. Lundberg (2019). "Peri-implant 
crevicular fluid proteome before and after adjunctive enamel matrix derivative 
treatment of peri-implantitis." J Clin Periodontol 46(6): 669-677. 
Etter, T. H., I. Hakanson, N. P. Lang, P. M. Trejo and R. G. Caffesse (2002). 
"Healing after standardized clinical probing of the perlimplant soft tissue seal: 
a histomorphometric study in dogs." Clin Oral Implants Res 13(6): 571-580. 
Faot, F., G. G. Nascimento, A. M. Bielemann, T. D. Campão, F. R. M. Leite and 
M. Quirynen (2015). "Can Peri-Implant Crevicular Fluid Assist in the Diagnosis 
of Peri-Implantitis? A Systematic Review and Meta-Analysis." Journal of 
Periodontology 86(5): 631-645. 
Geidenstam, N., Y. H. Hsu, C. M. Astley, J. M. Mercader, M. Ridderstrale, M. 
E. Gonzalez, C. Gonzalez, J. N. Hirschhorn and R. M. Salem (2019). "Using 
metabolite profiling to construct and validate a metabolite risk score for 
predicting future weight gain." PLoS One 14(9): e0222445. 
Ghassib, I., Z. Chen, J. Zhu and H. L. Wang (2019). "Use of IL-1 beta, IL-6, TNF-
alpha, and MMP-8 biomarkers to distinguish peri-implant diseases: A 
systematic review and meta-analysis." Clin Implant Dent Relat Res 21(1): 190-
207. 
Gurlek, O., P. Gumus, C. J. Nile, D. F. Lappin and N. Buduneli (2017). 
"Biomarkers and Bacteria Around Implants and Natural Teeth in the Same 
Individuals." J Periodontol 88(8): 752-761. 
Hall, J., N. G. Pehrson, A. Ekestubbe, T. Jemt and B. Friberg (2015). "A 
controlled, cross-sectional exploratory study on markers for the plasminogen 
system and inflammation in crevicular fluid samples from healthy, mucositis 
and peri-implantitis sites." Eur J Oral Implantol 8(2): 153-166. 
Heitz-Mayfield, L. J. and N. P. Lang (2010). "Comparative biology of chronic 
and aggressive periodontitis vs. peri-implantitis." Periodontol 2000 53: 167-181. 
Heitz-Mayfield, L. J. A. and G. E. Salvi (2018). "Peri-implant mucositis." Journal 
of Periodontology 89(S1): S257-S266. 
Kim, J. W., R. E. Wolff, P. Gaillard and L. F. Wolff (2015). "Gingival crevicular 
blood as a source to screen for diabetes control in a dental office setting." Am J 
Dent 28(2): 63-67. 
  
 90 
Kinney, J. S., T. Morelli, M. Oh, T. M. Braun, C. A. Ramseier, J. V. Sugai and W. 
V. Giannobile (2014). "Crevicular fluid biomarkers and periodontal disease 
progression." J Clin Periodontol 41(2): 113-120. 
Klysz, D., X. Tai, P. A. Robert, M. Craveiro, G. Cretenet, L. Oburoglu, C. 
Mongellaz, S. Floess, V. Fritz, M. I. Matias, C. Yong, N. Surh, J. C. Marie, J. 
Huehn, V. Zimmermann, S. Kinet, V. Dardalhon and N. Taylor (2015). 
"Glutamine-dependent alpha-ketoglutarate production regulates the balance 
between T helper 1 cell and regulatory T cell generation." Sci Signal 8(396): ra97. 
Kuboniwa, M., A. Sakanaka, E. Hashino, T. Bamba, E. Fukusaki and A. Amano 
(2016). "Prediction of Periodontal Inflammation via Metabolic Profiling of 
Saliva." J Dent Res 95(12): 1381-1386. 
Lee, S. H., J. W. Suh, B. C. Chung and S. O. Kim (1998). "Polyamine profiles in 
the urine of patients with leukemia." Cancer Lett 122(1-2): 1-8. 
Liebsch, C., V. Pitchika, C. Pink, S. Samietz, G. Kastenmuller, A. Artati, K. 
Suhre, J. Adamski, M. Nauck, H. Volzke, N. Friedrich, T. Kocher, B. Holtfreter 
and M. Pietzner (2019). "The Saliva Metabolome in Association to Oral Health 
Status." J Dent Res 98(6): 642-651. 
Loos, B. G. and S. Tjoa (2005). "Host-derived diagnostic markers for 
periodontitis: do they exist in gingival crevice fluid?" Periodontol 2000 39: 53-
72. 
Ma, J., U. Kitti, R. Hanemaaijer, O. P. Teronen, T. A. Sorsa, S. Natah, E. K. 
Tensing and Y. T. Konttinen (2003). "Gelatinase B is associated with peri-
implant bone loss." Clin Oral Implants Res 14(6): 709-713. 
Ma, J., U. Kitti, O. Teronen, T. Sorsa, V. Husa, P. Laine, H. Ronka, T. Salo, C. 
Lindqvist and Y. T. Konttinen (2000). "Collagenases in different categories of 
peri-implant vertical bone loss." J Dent Res 79(11): 1870-1873. 
Marchesan, J. T., T. Morelli, K. Moss, S. P. Barros, M. Ward, W. Jenkins, M. B. 
Aspiras and S. Offenbacher (2015). "Association of Synergistetes and 
Cyclodipeptides with Periodontitis." J Dent Res 94(10): 1425-1431. 
Misch, C. E., M. L. Perel, H. L. Wang, G. Sammartino, P. Galindo-Moreno, P. 
Trisi, M. Steigmann, A. Rebaudi, A. Palti, M. A. Pikos, D. Schwartz-Arad, J. 
Choukroun, J. L. Gutierrez-Perez, G. Marenzi and D. K. Valavanis (2008). 
"Implant success, survival, and failure: the International Congress of Oral 
Implantologists (ICOI) Pisa Consensus Conference." Implant Dent 17(1): 5-15. 
Monov, G., G. D. Strbac, M. Baron, B. Kandler, G. Watzek and R. Gruber (2006). 
"Soluble RANKL in crevicular fluid of dental implants: a pilot study." Clin 
Implant Dent Relat Res 8(3): 135-141. 
Murata, M., J. Tatsumi, Y. Kato, S. Suda, Y. Nunokawa, Y. Kobayashi, H. 
Takeda, H. Araki, K. Shin, K. Okuda, T. Miyata and H. Yoshie (2002). 
"Osteocalcin, deoxypyridinoline and interleukin-1beta in peri-implant 
  
 91 
crevicular fluid of patients with peri-implantitis." Clin Oral Implants Res 13(6): 
637-643. 
Nomura, T., A. Ishii, H. Shimizu, N. Taguchi, H. Yoshie, H. Kusakari and K. 
Hara (2000). "Tissue inhibitor of metalloproteinases-1, matrix 
metalloproteinases-1 and -8, and collagenase activity levels in peri-implant 
crevicular fluid after implantation." Clin Oral Implants Res 11(5): 430-440. 
Ozeki, M., T. Nozaki, J. Aoki, T. Bamba, K. R. Jensen, S. Murakami and M. 
Toyoda (2016). "Metabolomic Analysis of Gingival Crevicular Fluid Using Gas 
Chromatography/Mass Spectrometry." Mass Spectrom (Tokyo) 5(1): A0047. 
Panagakos, F. S., H. Aboyoussef, R. Dondero and J. J. Jandinski (1996). 
"Detection and measurement of inflammatory cytokines in implant crevicular 
fluid: a pilot study." Int J Oral Maxillofac Implants 11(6): 794-799. 
Patini, R., E. Staderini, C. Lajolo, L. Lopetuso, H. Mohammed, L. Rimondini, V. 
Rocchetti, F. Franceschi, M. Cordaro and P. Gallenzi (2018). "Relationship 
between oral microbiota and periodontal disease: a systematic review." Eur Rev 
Med Pharmacol Sci 22(18): 5775-5788. 
Rakic, M., V. Lekovic, N. Nikolic-Jakoba, D. Vojvodic, A. Petkovic-Curcin and 
M. Sanz (2013). "Bone loss biomarkers associated with peri-implantitis. A cross-
sectional study." Clin Oral Implants Res 24(10): 1110-1116. 
Ramseier, C. A., S. Eick, C. Bronnimann, D. Buser, U. Bragger and G. E. Salvi 
(2016). "Host-derived biomarkers at teeth and implants in partially edentulous 
patients. A 10-year retrospective study." Clin Oral Implants Res 27(2): 211-217. 
Razzouk, S. and C. Teixeira (2010). "Personalized implant therapy: new 
perspectives in bone remodeling assessment." N Y State Dent J 76(4): 50-52. 
Recker, E. N., G. Avila-Ortiz, C. L. Fischer, K. Pagan-Rivera, K. A. Brogden, D. 
V. Dawson and S. Elangovan (2015). "A cross-sectional assessment of 
biomarker levels around implants versus natural teeth in periodontal 
maintenance patients." J Periodontol 86(2): 264-272. 
Renvert, S., C. Lindahl and G. Rutger Persson (2012). "The incidence of peri-
implantitis for two different implant systems over a period of thirteen years." J 
Clin Periodontol 39(12): 1191-1197. 
Renvert, S., G. R. Persson, F. Q. Pirih and P. M. Camargo (2018). "Peri-implant 
health, peri-implant mucositis, and peri-implantitis: Case definitions and 
diagnostic considerations." Journal of Periodontology 89(S1): S304-S312. 
Renvert, S., C. Widen and R. G. Persson (2017). "Cytokine and microbial profiles 
in relation to the clinical outcome following treatment of peri-implantitis." Clin 
Oral Implants Res 28(9): 1127-1132. 
Roccuzzo, M., D. M. Layton, A. Roccuzzo and L. J. Heitz-Mayfield (2018). 
"Clinical outcomes of peri-implantitis treatment and supportive care: A 
systematic review." Clin Oral Implants Res 29 Suppl 16: 331-350. 
  
 92 
Romano, F., G. Meoni, V. Manavella, G. Baima, G. M. Mariani, S. Cacciatore, L. 
Tenori and M. Aimetti (2019). "Effect of non-surgical periodontal therapy on 
salivary metabolic fingerprint of generalized chronic periodontitis using 
nuclear magnetic resonance spectroscopy." Arch Oral Biol 97: 208-214. 
Romano, F., G. Meoni, V. Manavella, G. Baima, L. Tenori, S. Cacciatore and M. 
Aimetti (2018). "Analysis of salivary phenotypes of generalized aggressive and 
chronic periodontitis through nuclear magnetic resonance-based 
metabolomics." J Periodontol 89(12): 1452-1460. 
Sahrmann, P., T. Attin and P. R. Schmidlin (2011). "Regenerative treatment of 
peri-implantitis using bone substitutes and membrane: a systematic review." 
Clin Implant Dent Relat Res 13(1): 46-57. 
Sakanaka, A., M. Kuboniwa, E. Hashino, T. Bamba, E. Fukusaki and A. Amano 
(2017). "Distinct signatures of dental plaque metabolic byproducts dictated by 
periodontal inflammatory status." Sci Rep 7: 42818. 
Sakanaka, A., M. Kuboniwa, H. Takeuchi, E. Hashino and A. Amano (2015). 
"Arginine-Ornithine Antiporter ArcD Controls Arginine Metabolism and 
Interspecies Biofilm Development of Streptococcus gordonii." J Biol Chem 
290(35): 21185-21198. 
Schierano, G., G. Pejrone, P. Brusco, A. Trombetta, G. Martinasso, G. Preti and 
R. A. Canuto (2008). "TNF-alpha TGF-beta2 and IL-1beta levels in gingival and 
peri-implant crevicular fluid before and after de novo plaque accumulation." J 
Clin Periodontol 35(6): 532-538. 
Schirra, H. J. and P. J. Ford (2017). "NMR-Based Metabolomics of Oral 
Biofluids." Methods Mol Biol 1537: 79-105. 
Schwarz, F., J. Derks, A. Monje and H.-L. Wang (2018). "Peri-implantitis." 
Journal of Periodontology 89(S1): S267-S290. 
Sorsa, T., T. Tervahartiala, J. Leppilahti, M. Hernandez, J. Gamonal, A. M. 
Tuomainen, A. Lauhio, P. J. Pussinen and P. Mantyla (2011). "Collagenase-2 
(MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular 
diseases. Therapeutic response to non-antimicrobial properties of 
tetracyclines." Pharmacol Res 63(2): 108-113. 
Strand, E., I. L. Tangen, K. E. Fasmer, H. Jacob, M. K. Halle, E. A. Hoivik, B. 
Delvoux, J. Trovik, I. S. Haldorsen, A. Romano and C. Krakstad (2019). "Blood 
Metabolites Associate with Prognosis in Endometrial Cancer." Metabolites 
9(12). 
Strbac, G. D., G. Monov, S. Cei, B. Kandler, G. Watzek and R. Gruber (2006). 
"Cathepsin K levels in the crevicular fluid of dental implants: a pilot study." J 
Clin Periodontol 33(4): 302-308. 




Sugimoto, M., D. T. Wong, A. Hirayama, T. Soga and M. Tomita (2010). 
"Capillary electrophoresis mass spectrometry-based saliva metabolomics 
identified oral, breast and pancreatic cancer-specific profiles." Metabolomics 
6(1): 78-95. 
Tonetti, M. S., H. Greenwell and K. S. Kornman (2018). "Staging and grading of 
periodontitis: Framework and proposal of a new classification and case 
definition." J Periodontol 89 Suppl 1: S159-s172. 
Vinayavekhin, N., E. A. Homan and A. Saghatelian (2010). "Exploring disease 
through metabolomics." ACS Chem Biol 5(1): 91-103. 
Vinayavekhin, N. and A. Saghatelian (2010). "Untargeted metabolomics." Curr 
Protoc Mol Biol Chapter 30: Unit 30.31.31-24. 
Wang, H. L., C. Garaicoa-Pazmino, A. Collins, H. S. Ong, R. Chudri and W. V. 
Giannobile (2016). "Protein biomarkers and microbial profiles in peri-
implantitis." Clin Oral Implants Res 27(9): 1129-1136. 
Wendisch, V. F. (2017). "Microbial Production of Amino Acid-Related 
Compounds." Adv Biochem Eng Biotechnol 159: 255-269. 
Wishart, D. S. (2008). "Quantitative metabolomics using NMR." TrAC Trends 
in Analytical Chemistry 27(3): 228-237. 
Wohlfahrt, J. C., A. M. Aass, F. Granfeldt, S. P. Lyngstadaas and J. E. Reseland 
(2014). "Sulcus fluid bone marker levels and the outcome of surgical treatment 
of peri-implantitis." J Clin Periodontol 41(4): 424-431. 
Wolff, L., G. Dahlen and D. Aeppli (1994). "Bacteria as Risk Markers for 
Periodontitis." J Periodontol 65 Suppl 5S: 498-510. 
Wolff, L. F., Q. T. Smith, W. K. Snyder, J. A. Bedrick, W. F. Liljemark, D. A. 
Aeppli and C. L. Bandt (1988). "Relationship between lactate dehydrogenase 
and myeloperoxidase levels in human gingival crevicular fluid and clinical and 
microbial measurements." J Clin Periodontol 15(2): 110-115. 
Xu, L., Z. Yu, H. M. Lee, M. S. Wolff, L. M. Golub, T. Sorsa and H. Kuula (2008). 
"Characteristics of collagenase-2 from gingival crevicular fluid and peri-
implant sulcular fluid in periodontitis and peri-implantitis patients: pilot 
study." Acta Odontol Scand 66(4): 219-224. 
Yamalik, N., S. Gunday, S. Uysal, K. Kilinc, E. Karabulut and T. F. Tozum 
(2012). "Analysis of cathepsin-K activity at tooth and dental implant sites and 
the potential of this enzyme in reflecting alveolar bone loss." J Periodontol 
83(4): 498-505. 
Yatsuoka, W., T. Ueno, K. Miyano, Y. Uezono, A. Enomoto, M. Kaneko, S. Ota, 
T. Soga, M. Sugimoto and T. Ushijima (2019). "Metabolomic profiling reveals 
salivary hypotaurine as a potential early detection marker for medication-
related osteonecrosis of the jaw." PLoS One 14(8): e0220712. 
  
 94 
Yu, S., L. Ding, D. Liang and L. Luo (2018). "Porphyromonas gingivalis inhibits 
M2 activation of macrophages by suppressing alpha-ketoglutarate production 
in mice." Mol Oral Microbiol 33(5): 388-395. 
Zani, S. R., K. Moss, J. A. Shibli, E. R. Teixeira, R. de Oliveira Mairink, T. 
Onuma, M. Feres and R. P. Teles (2016). "Peri-implant crevicular fluid 
biomarkers as discriminants of peri-implant health and disease." J Clin 
Periodontol 43(10): 825-832. 
 
